Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/26—Glucagons
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• This application relates to the use of agents to control appetite, feeding, food intake, energy expenditure and calorie intake, particularly in the field of obesity.
• obesity is complex and multi-factorial. Increasing evidence suggests that obesity is not a simple problem of self-control but is a complex disorder involving appetite regulation and energy metabolism, h addition, obesity is associated with a variety of conditions associated with increased morbidity and mortality in a population. Although the etiology of obesity is not definitively established, genetic, metabolic, biochemical, cultural and psychosocial factors are believed to contribute. In general, obesity has been described as a condition in which excess body fat puts an individual at a health risk. There is strong evidence that obesity is associated with increased morbidity and mortality. Disease risk, such as cardiovascular disease risk and type 2 diabetes disease risk, increases independently with increased body mass index (BMI).
• BMI body mass index
• this risk has been quantified as a five percent increase in the risk of cardiac disease for females, and a seven percent increase in the risk of cardiac disease for males, for each point of a BMI greater than 24.9 (see Kenchaiah et al., N. Engl. J. Med. 347:305, 2002; Massie, N. Engl J. Med. 347:358, 2002).
• weight loss in obese persons reduces important disease risk factors. Even a small weight loss, such as 10% of the initial body weight in both overweight and obese adults has been associated with a decrease in risk factors such as hypertension, hyperlipidemia, and hyperglycemia.
• peripheral administration of PYY, or an agonist thereof, to a subject results in decreased food intake, caloric intake, and appetite, and an alteration in energy metabolism.
• the subject can be any subject, including, but not limited to, a human subject.
• the subject desires to lose weight, is obese, overweight, or suffers from a weight-related disorder.
• PYY 3 . 36 can preferably be administered to the subject.
• a method for decreasing calorie intake in a subject.
• the method includes peripherally administering a therapeutically effective amount of PYY or an agonist thereof and GLP-1 or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject.
• a method for decreasing appetite in a subject.
• the method includes peripherally administering a therapeutically effective amount of PYY or an agonist thereof and GLP-1 or an agonist thereof to the subject, thereby decreasing the appetite of the subject.
• a method is disclosed for decreasing food intake in a subject. The method includes peripherally administering a therapeutically effective amount of PYY or an agonist thereof, and GLP-1 or an agonist thereof to the subject, thereby decreasing the food intake of the subject.
• a method for increasing energy expenditure in a subject.
• the method includes peripherally administering a therapeutically effective amount of PYY or an agonist thereof, and GLP-1 or an agonist thereof to the subject, thereby increasing energy expenditure in the subject.
• a method for decreasing calorie intake, food intake, or appetite in a human subject includes peripherally injecting a therapeutically effective amount of PYY or an agonist thereof in a pharmaceutically acceptable carrier to the subject in a pulse dose, thereby decreasing the calorie intake, food intake, or appetite of the subject, and also administering GLP-1 or an agonist thereof.
• the GLP-1 or an agonist thereof may be administered simultaneously or substantially simultaneously as the PYY or agonist thereof, or sequentially, in any order.
• the PYY or agonist thereof and the GLP-1 or agonist thereof may be aciministered in a single pharmaceutical composition or in separate compositions, and they may be administered by the same route or my different routes.
• Fig. 1 is a set of diagrams and digital images showing the generation of transgenic mice expressing EGFP in ARC POMC neurons.
• Fig. la is a schematic diagram of the structure of the POMC-EGFP transgene.
• Fig. lb is a digital image showing the identification of a single POMC neuron (arrowhead on recording electrode tip) by EGFP fluorescence (upper) and IR-DIC microscopy (lower) in a living ARC slice prior to electrophysiological recordings.
• Fig. lc is a set of digital images showing the co-localization (bright, on right) of EGFP (left) and ⁇ -endorphin immunoreactivity (middle) in ARC POMC neurons. Scale bars: b & c, 50 ⁇ m.
• Fig.2 is a tracing and graphs showing activation of MOP-Rs hyperpolarizes the EGFP-labeled POMC neurons by opening G protein-coupled inwardly-rectifying potassium channels.
• Fig. 2a is a tracing showing met-enkephalin hyperpolarizes POMC neurons and inhibits all action potentials. The horizontal bar indicates the time when 30 ⁇ M Met-Enk was bath-applied to the slice.
• Fig. 2b is a graph showing met-enkephalin current and reversal potential is shifted by extracellular K + concentration.
• Fig. 2c is a graph showing met-enkephalin activates MOP-Rs on POMC neurons.
• Fig. 3 are tracings and graphs demonstrating that leptin depolarizes POMC neurons via a non-specific cation channel, and decreases GAB Aergic tone onto POMC cells.
• Fig. 3a is a tracing demonstrating that leptin depolarizes POMC neurons and increases the frequency of action potentials within 1 to 10 minutes of addition.
• the figure is a representative example of recordings made from 77 POMC neurons.
• Fig. 3 c is a graph showing that leptin depolarizes POMC cells by activating a nonspecific cation current. The figure is representative of the response in 10 cells.
• Fig. 3d is a graph showing that leptin decreases the frequency of IPSCs in POMC cells. The figure is an example of 5 cells in which leptin (100 nM) decreased the frequency of IPSCs.
• Fig. 3e is a tracing demonstrating that leptin had no effect on 5 adjacent non-fluorescent ARC neurons.
• Fig. 3f is a tracing showing that leptin hyperpolarized 5 non-fluorescent ARC neurons.
• Fig. 4 is a set of images showing that the GAB Aergic inputs to POMC cells are from NPY neurons that co-express GABA.
• Fig. 4a is a graph showing that NPY decreases the frequency of mini IPSCs in POMC neurons.
• Fig. 4b is a graph demonstrating that D-Trp 8 - ⁇ MSH (7nM), a dose that selectively activates MC3-R, increases the frequency of GABAergic IPSCs in POMC neurons.
• Fig.4c is a tracing showing that D-Trp 8 - ⁇ MSH hyperpolarizes POMC neurons.
• Figs. 4a, 4b and 4c are representative. Fig.
• NPY nerve terminals black, arrowheads
• POMC neuronal soma grey
• Scale bar 10 ⁇ m
• Fig. 4e is a digital image showing expression of GABA and NPY in nerve terminals synapsing onto POMC neurons in the ARC.
• GABA immunoreactivity (10 nm gold particles, arrowheads without tail) and NPY immunoreactivity (25 nm gold particles, arrows with tail) are in separate vesicle populations co-localized within synaptic boutons that make direct contact with the soma of POMC neurons (DAB contrasted with uranyl acetate and lead citrate, diffuse black in cytoplasm).
• Scale bar 1 ⁇ m.
• Fig.4f is a diagram of the model of NPY/GABA and POMC neurons in the ARC.
• Fig. 5 is a set of graphs relating to the feeding response to PYY 3 . 36 in rats.
• 5a is a bar graph of dark-phase feeding tabulating food intake after intraperitoneal injection of PYY 3 . 36 .
• Fig. 5b is a bar graph of food intake after intraperitoneal injection of PYY 3 . 36 . Fasted rats were injected with PYY 3 .
• Fig. 5c is a bar graph of cumulative food intake after intraperitoneal injection of saline or PYY 3 . 36 . Fasted rats were injected with either saline (closed bars) or PYY 3 . 36 5 ⁇ g/100g (open bars) and cumulative food intake measured at the time points indicated. Results are expressed as mean ⁇ s.e.m.
• Fig. 6 is a set of digital images of c-fos expression in Pomc-EGFP mice.
• Figs. 6a and 6b are digital images of representative sections (bregma-1.4 mm ) of c-fos expression in the arcuate nucleus of Pomc-EGFP mice response to intraperitoneal saline (Fig. 6a) or PYY 3 . 36 (5 ⁇ g/100g) (Fig. 6b).
• Scale bar 100 ⁇ m. 3N, third ventricle; Arc, arcuate nucleus.
• Figs. 6c and 6d are digital images of representative sections showing POMC-EGFP neurons (Fig. 6c) and c-fos immunoreactivity (Fig. 6d) either co-localizing (bright arrows) or alone (single darker arrow).
• Fig. 7 is a set of bar graphs relating to intra-arcuate PYY 3 . 3 6in rats and feeding effects of IP PYY 3 . 36 in Y2r- null mice.
• Figs. 7b and 7c are bar graphs of feeding response to PYY 3 . 36 in 72r-null mice following IP administration: wild type littermates mice (Fig.
• Fig. 8 is a set of images relating to the electrophysiological and neuropeptide responses to PYY 3 . 36 and Y2A.
• PYY 3 . 38 was administered at time D for 3 minutes; baseline, -3 to 0 minute; PYY 3 . 36 , 2-5 minutes; and wash-out, 8-11 minutes.
• Inset shows a representative recording of membrane potential and action potential frequency.
• Fig. 8b is a graph of the effect if PYY 3 .
• Fig. 8d and 8e are bar graphs showing NPY (Fig. 8d) and %-MSH (Fig.
• hypothalamic explants in response to Y2A.
• Fig. 9 is a set of graphs showing the effect of PYY 3 . 36 infusion on appetite and food intake in human subjects.
• Fig. 9a is a graph of the calorie intake from a "free-choice" buffet meal 2 hours after infusion with saline or PYY 3 . 36 .
• the thin lines indicate individual changes in calorie intake for each subject between saline and PYY 3 . 36 administration.
• Fig. 9b is a graph of the 24-hour calorie intake following infiision with saline or PYY 3 . 36 . Total calorie intake, as assessed by food diaries, is shown for the 24-hour period following either saline or PYY 3 .
• Fig. 9c is a graph of the appetite score (relative scale).
• Visual analogue scores (Raben et al., Rr. J. Nutr. 73, 517-30, 1995) show perceived hunger during and after infusions. The results are presented as change from baseline scores and are the mean ⁇ s.e.m. for all 12 subjects.
• Fig. 10 shows plasma PYY 3 . 36 levels following subcutaneous administration of 10 nmols PYY 3 . 36 (broken line) and 20 nmols PYY 3 . 36 (sohd line).
• Fig. 11 shows the effect on 1-hour food intake in non-fasted rats of IP administration of GLP-1 in the presence or absence of concomitant exendin 9-39 in the arcuate nucleus of the rat.
• S Saline
• G GLP-1 (25 nmol/kg)
• Ex exendin 9-39 (20 nmoles/kg).
• Fig. 12 shows the effects of co-administration of PYY 3 . 36 and GLP-1 on 1- hour food intake in non-fasted rats injected (intraperitoneally) prior to the onset of the dark phase.
• Co-administration is GLP-1 30 ⁇ g/kg and PYY 3 . 36 3 ⁇ g/kg combined.
• nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.
• ⁇ -MSH alpha melanocortin stimulating hormone
• Arc arcuate nucleus
• EPSP excitatory postsynaptic potential
• GABA ⁇ aminobutyric acid
• GFP green fluorescent protein
• GLP-1 glucagons-like peptide- 1
• ICV intracerebroventricular
• IP intraperitoneal
• IPSC inhibitory postsynaptic current
• MOP-R ⁇ -opiod receptor
• NPY neuropeptide Y
• Oxm oxyntomodulin pmol: picomole
• POMC proopiomelanocortin
• RPA RNase protection assay s.e.m: standard error of the mean
• TH tyrosine hydroxylase
• ⁇ M micromolar
• Y2A N-acetyl (Leu 28 , Leu 31 ) NPY (24-36)
• Action potential A rapidly propagated electrical message that speeds along an axon of a neuron and over the surface membrane of many muscle and glandular cells. In axons they are brief, travel at constant velocity, and maintain a constant amplitude.
• the action potential is a membrane potential change caused by the flow of ions through ion channels in the membrane.
• an action potential is a regenerative wave of sodium permeability.
• Animal Living multi-cellular vertebrate organisms, a category that includes, for example, mammals and birds.
• mammal includes both human and non-human mammals.
• subject includes both human and veterinary subjects.
• Anorexia A lack or loss of the appetite for food.
• anorexia is a result of "anorexia nervosa.”
• This is an eating disorder primarily affecting females, usually with onset in adolescence, characterized by refusal to maintain a normal minimal body weight, intense fear of gaining weight or becoming obese, and a disturbance of body image resulting in a feeling of being fat or having fat in certain areas even when extremely emaciated, undue reliance on body weight or shape for self-evaluation, and amenorrhea.
• Associated features often include denial of the illness and resistance to psychotherapy, depressive symptoms, markedly decreased libido, and obsessions or peculiar behavior regarding food, such as hoarding.
• the disorder is divided into two subtypes, a restricting type, in which weight loss is achieved primarily through diet or exercise, and a binge- eating/purging type, in which binge eating or purging behavior also occur regularly.
• Antagonist A substance that tends to nullify the action of another, as an agent that binds to a cell receptor without eliciting a biological response, blocking binding of substances that could elicit such responses.
• Appetite A natural desire, or longing for food. In one embodiment, appetite is measured by a survey to assess the desire for food. Increased appetite generally leads to increased feeding behavior.
• Appetite Suppressants Compounds that decrease the desire for food.
• Commercially available appetite suppressants include, but are not limited to, amfepramone (diethylpropion), phentermine, mazindol and phenylpropanolamine fenfluramine, dexfenfluramine, and fluoxetine.
• Binding A specific interaction between two molecules, such that the two molecules interact. Binding can be specific and selective, so that one molecule is bound preferentially when compared to another molecule. In one embodiment, specific binding is identified by a disassociation constant (K d ).
• Body Mass Index A mathematical formula for measuring body mass, also sometimes called Quetelet's Index. BMI is calculated by dividing weight (in kg) by height 2 (in meters 2 ). The current standards for both men and women accepted as "normal” are a BMI of 20-24.9 kg/m 2 . In one embodiment, a BMI of greater than 25 kg/m 2 can be used to identify an obese subject. Grade I obesity corresponds to a BMI of 25-29.9 kg/m 2 . Grade II obesity corresponds to a BMI of 30-40 kg/m 2 ; and Grade III obesity corresponds to a BMI greater than 40 kg/m 2 (Jequier, Am. JClin. Nutr. 45:1035-47, 1987).
• c-fos The cellular homologue of the viral v-fos oncogene found in FBJ (Finkel-Biskis-Jinkins) and FBR murine osteosarcoma viruses (MSV).
• the human fos gene maps to chromosome 14q21-q31. Human fos has been identified as TIS- 28.
• C-fos is thought to have an important role in signal transduction, cell proliferation, and differentiation. It is a nuclear protein which, in combination with other transcription factors (for example, jun) acts as a trans-activating regulator of gene expression.
• C-fos is an immediate early response gene, which are believed to play a key role in the early response of cells to growth factors.
• C-fos is involved also in the control of cell growth and differentiation of embryonic hematopoietic cells and neuronal cells.
• the human c-fos coding amino acid and nucleic sequences are known (e.g., see Verma et al., Cold Spring Harb. Symp. Quant. Biol. 51, 949, 1986; GenBank Accession Nos. K00650 and M16287, and is available on the internet).
• Caloric intake or calorie intake The number of calories (energy) consumed by an individual.
• Calorie A unit of measurement in food.
• Conservative variation The replacement of an amino acid residue by another, biologically similar residue.
• conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine, and the like.
• conservative variation also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.
• Non-limiting examples of conservative amino acid substitutions include those listed below:
• Depolarization An increase in the membrane potential of a cell. Certain stimuli reduce the charge across the plasma membrane. These can be electrical stimuli (which open voltage-gated channels), mechanical stimuli (which activate mechanically-gated channels) or certain neurotransmitters (which open ligand-gated channels). In each case, the facilitated diffusion of sodium into the cell increases the resting potential at that spot on the cell creating an excitatory postsynaptic potential (EPSP). Depolarizations can also be generated by decreasing the frequency of inhibitory postsynaptic currents (IPSCs), these are due to inhibitory neurotransmitters facilitating the influx of chloride ions into the cell, creating an rPSC.
• IPSC inhibitory postsynaptic currents
• Diabetes A failure of cells to transport endogenous glucose across their membranes either because of an endogenous deficiency of insulin and/or a defect in insulin sensitivity. Diabetes is a chronic syndrome of impaired carbohydrate, protein, and fat metabolism owing to insufficient secretion of insulin or to target tissue insulin resistance. It occurs in two major forms: insulin-dependent diabetes mellitus (IDDM, type I) and non-insulin dependent diabetes mellitus (NIDDM, type H) which differ in etiology, pathology, genetics, age of onset, and treatment.
• IDDM insulin-dependent diabetes mellitus
• NIDDM non-insulin dependent diabetes mellitus
• Diabetes type I or insulin dependent diabetes mellitus (IDDM) is caused by the destruction of ⁇ cells, which results in insufficient levels of endogenous insulin.
• IDDM insulin dependent diabetes mellitus
• Diabetes type ⁇ or non-insulin dependent diabetes, results from a defect in both the body's sensitivity to insulin, and a relative deficiency in insulin production.
• Exendin A 39-amino acid peptide isolated from the salivary glands of the Gila monster (Heloderma suspectum) (Eng J et al J Biol Chem 267:7402-7405, 1992), see SEQ ID NO:341. Exendin is an example of an agonist at the GLP-1 receptor. Molecules derived from exendin-4 and that also have GLP-1 agonist activity are further examples of GLP-1 agonists.
• Food intake The amount of food consumed by an individual. Food intake can be measured by volume or by weight. In one embodiment, food intake is the total amount of food consumed by an individual. In another embodiment, food intake is the amount of proteins, fat, carbohydrates, cholesterol, vitamins, minerals, or any other food component, of the individual.
• Protein intake refers to the amount of protein consumed by an individual.
• fat intake refers to the amount of protein consumed by an individual.
• carbohydrate intake refers to the amount of proteins, fat, carbohydrates, cholesterol, vitamins, or minerals consumed by an individual.
• Glucagon-like peptide-1 Peptides produced by processing of preproglucogon, which is a 160 amino acid polypeptide, in the central nervous system (CNS) and the intestine.
• GLP-1 (1-37) is the initial product.
• GLP-1 (1-37) is amidated by post-translational processing to yield GLP-1 (1-36) NH, or is enzymatically processed to give GLP-1 (7-37) (SEQ ID NO: 338).
• GLP-1 (7-37) can be amidated to give GLP-1 (7-36) amide (SEQ ID NO: 339), which is the most biologically active form. GLP-1 is released into the circulation in response to nutrient intake. Intestinal cells secrete GLP-1 (7-37) and GLP-1 (7-36) amide in a ratio of 1 to 5.
• GLP-1 receptors are found in the brainstem, arcuate nucleus and paraventricular nucleus. Physiological actions of GLP-1 in man include stimulation of insulin release, suppression of gastric acid secretion and slowing of gastric emptying.
• a GLP-1 agonist is a peptide, small molecule, or chemical compound that preferentially binds to the GLP-1 receptor and stimulate sthe same biological activity as GLP-1.
• an agonist for the GLP-1 receptor binds to the receptor with an equal or greater affinity than a GLP-1 peptide.
• an agonist selectively binds the GLP-1 receptor, as compared to binding to another receptor.
• Kd dissociation constant
• GLP-1 agonists include GLP-1 related peptides and peptides that result from natural or synthetic enzymatic or chemical processing of a GLP-1 peptide or a related peptide.
• Hyperpolarization A decrease in the membrane potential of a cell. Inhibitory neurotransmitters inhibit the transmission of nerve impulses via hyperpolarization. This hyperpolarization is called an inhibitory postsynaptic potential (IPSP). Although the threshold voltage of the cell is unchanged, a hyperpolarized cell requires a stronger excitatory stimulus to reach threshold.
• IIPSP inhibitory postsynaptic potential
• Inhibitory Postsynaptic Current A current that inhibits an electrophysiological parameter of a postsynaptic cell.
• the potential of a postsynaptic cell can be analyzed to determine an effect on a presynaptic cell.
• the postsynaptic cell is held in voltage clamp mode, and postsynaptic currents are recorded. If necessary, antagonists of other classes of current can be added.
• antagonists of other classes of current can be added.
• to record GABAergic IPSCs blockers of excitatory channels or receptors can be added. The instantaneous frequency over time is then determined.
• IPSCs give a measure of the frequency of GABA release from an NPY neuron.
• measurement of IPSC frequency is a gauge of the inhibitory tone that POMC neurons are receiving, and can be used to assess the effect of an agonist of PYY.
• Membrane potential The electrical potential of the interior of the cell with respect to the environment, such as an external bath solution.
• One of skill in the art can readily assess the membrane potential of a cell, such as by using conventional whole cell techniques. Activation of a cell is associated with less negative membrane potentials (for example shifts from about -50 mV to about -40 mV). - These changes in potential increase the likelihood of action potentials, and thus lead to an increase in the rate of action potentials.
• the rate of action potentials can be assessed using many approaches, such as using conventional whole cell access, or using, for example, perforated-patch whole- cell and cell-attached configurations.
• the absolute voltage or current is not assessed, rather the frequency of rapid deflections characteristic of action potentials is assessed, as a function of time (therefore this frequency is an instantaneous frequency, reported in "bins").
• This time component can be related to the time at which a compound, such as a PYY agonist, is applied to the bath to analyze the effect of the compound, such as the PYY agonist, on action potential firing rate.
• Neuropeptide Y A 36-amino acid peptide that is a neuropeptide identified in the mammalian brain. NPY is believed to be an important regulator in both the central and peripheral nervous systems and influences a diverse range of physiological parameters, including effects on psychomotor activity, food intake, central endocrine secretion, and vasoactivity in the cardiovascular system. High concentrations of NPY are found in the sympathetic nerves supplying the coronary, cerebral, and renal vasculature and have contributed to vasoconstriction. NPY binding sites have been identified in a variety of tissues, including spleen, intestinal membranes, brain, aortic smooth muscle, kidney, testis, and placenta. In addition, binding sites have been reported in a number of rat and human cell lines.
• Neuropeptide Y (NPY) receptor has structure/activity relationships within the pancreatic polypeptide family. This family includes NPY, which is synthesized primarily in neurons; peptide YY (PYY), which is synthesized primarily by endocrine cells in the gut; and pancreatic polypeptide (PP), which is synthesized primarily by endocrine cells in the pancreas. These 36 amino acid peptides have a compact helical structure involving an amino acid structure, termed a "PP-fold" in the middle of the peptide. NPY binds to several receptors, including the Yl , Y2, Y3, Y4 (PP), Y5, Y6, and Y7 receptors.
• PP pancreatic polypeptide
• the Yl receptor is generally considered to be postsynaptic and mediates many of the known actions of neuropeptide Y in the periphery. Originally, this receptor was described as having poor affinity for C- terminal fragments of neuropeptide Y, such as the 13-36 fragment, but interacts with the full length neuropeptide Y and peptide YY with equal affinity (e.g., see PCT publication WO 93/09227).
• the Y2 receptor is distinguished from Yl by exhibiting affinity for C-terminal fragments of neuropeptide Y.
• the Y2 receptor is most often differentiated by the affinity of neuropeptide Y(13-36), although the 3-36 fragment of neuropeptide Y and peptide YY provides improved affinity and selectivity (see Dumont et al., Society for Neuroscience Abstracts 19:726, 1993).
• Signal transmission through both the Yl and the Y2 receptors are coupled to the inhibition of adenylate cyclase. Binding to the Y-2 receptor was also found to reduce the intracellular levels of calcium in the synapse by selective inhibition of N-type calcium channels.
• Y-2 receptor like the Yl receptors, exhibits differential coupling to second messengers (see U.S. Patent No. 6,355,478).
• Y2 receptors are found in a variety of brain regions, including the hippocampus, substantia nigra-lateralis, thalamus, hypothalamus, and brainstem. The human, murine, monkey and rat Y2 receptors have been cloned (e.g., see U.S. Patent No. 6,420,352 and U.S. Patent No. 6,355,478).
• a Y2 receptor agonist is a peptide, small molecule, or chemical compound that preferentially binds to the Y2 receptor and stimulates intracellular signaling.
• an agonist for the Y2 receptor binds to the receptor with an equal or greater affinity than NPY.
• an agonist selectively binds the Y2 receptor, as compared to binding to another receptor.
• Kd dissociation constant
• Normal Daily Diet The average food intake for an individual of a given species.
• a normal daily diet can be expressed in terms of caloric intake, protein intake, carbohydrate intake, and/or fat intake.
• a normal daily diet in humans generally comprises the following: about 2,000, about 2,400, or about 2,800 to significantly more calories.
• a normal daily diet in humans generally includes about 12 g to about 45 g of protein, about 120 g to about 610 g of carbohydrate, and about 11 g to about 90 g of fat.
• a low calorie diet would be no more than about 85%, and preferably no more than about 70%, of the normal caloric intake of a human individual.
• the caloric and nutrient requirements vary depending on the species and size of the animal.
• the total caloric intake per pound, as well as the percent distribution of protein, carbohydrate and fat varies with the age of the cat and the reproductive state.
• a general guideline for cats is 40 cal lb/day (18.2 cal/kg/day).
• About 30% to about 40% should be protein, about 7% to about 10% should be from carbohydrate, and about 50% to about 62.5% should be derived from fat intake.
• One of skill in the art can readily identify the normal daily diet of an individual of any species.
• Obesity A condition in which excess body fat may put a person at health risk (see Barlow and Dietz, Pediatrics 102:E29, 1998; National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Obes. Res. 6 (suppl. 2):51 S- 209S, 1998). Excess body fat is a result of an imbalance of energy intake and energy expenditure.
• the Body Mass Index (BMI) is used to assess obesity.
• BMI Body Mass Index
• a BMI of 25.0 kg/m 2 to 29.9 kg/m 2 is overweight, while a BMI of 30 kg/m 2 is obese.
• waist circumference is used to assess obesity.
• a waist circumference of 102 cm or more is considered obese, while in women a waist circumference of 89 cm or more is considered obese.
• Strong evidence shows that obesity affects both the morbidity and mortality of individuals.
• an obese individual is at increased risk for heart disease, non-insulin dependent (type 2) diabetes, hypertension, stroke, cancer (e.g. endometrial, breast, prostate, and colon cancer), dyslipidemia, gall bladder disease, sleep apnea, reduced fertility, and osteoarthritis, amongst others (see Lyznicki et al., Am. Fam. Phys. 63:2185, 2001).
• Overweight An individual who weighs more than their ideal body weight.
• An overweight individual can be obese, but is not necessarily obese.
• an overweight individual is any individual who desires to decrease their weight.
• an overweight individual is an individual with a BMI of 25.0 kg/m 2 to 29.9 kg/m 2
• Oxyntomodulin A further peptide produced by post-translational processing of preproglucagon in the CNS and intestine, see SEQ ID NO: 340.
• Agonists of oxyntomodulin may be identified as described above for agonists of GLP-1 and of NPY.
• OXM include oxyntomodulins of other species and also modified sequences, for example, sequences in which The term OXM used in this text also covers any analogue of the above OXM sequence, wherein the histidine residue at position 1 is maintained or replaced by an aromatic moiety carrying a positive charge or a derivative thereof, preferably wherein the moiety is an amino acid, more preferably wherein it is a histidine derivative, while 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 of the other amino acids in the above OXM sequence can be independently replaced by any other independently chosen amino acid, with the exception of histidine in position 1.
• any one or more (to 22) other alpha-amino acid residue in the sequence can be independently replaced by any other one alpha-amino acid residue.
• any amino acid residue other than histidine is replaced with a conservative replacement as well known in the art i.e. replacing an amino acid with one of a similar chemical type such as replacing one hydrophobic amino acid with another.
• 1 to 22 of the amino acids can be replaced. In addition to the replacement option above, this may be by a non-essential or modified or isomeric form of an amino acid.
• 1 to 22 amino acids can be replaced by an isomeric form (for example a D-amino acid), or a modified amino acid, for example a nor-amino acid (such as norleucine or norvaline) or a non-essential amino acid (such as taurine).
• 1 to 22 amino acids may be replaced by a corresponding or different amino acid linked via its side chain (for example gamma- linked glutamic acid). For each of the replacements discussed above, the histidine residue at position 1 is unaltered or defined above.
• 1, 2, 3, 4 or 5 of the amino acid residues can be removed from the OXM sequence with the exception of histidine at the 1 position (or as defined above).
• the deleted residues may be any 2, 3, 4 or 5 contiguous residues or entirely separate residues.
• the C-terminus of the OXM sequence may be modified to add further amino acid residues or other moieties.
• Pancreatic Polypeptide A 36 amino acid peptide produced by the pancreas that is has homology to PYY and NPY.
• Peripheral Administration Administration outside of the central nervous system. Peripheral administration does not include direct administration to the brain. Peripheral administration includes, but is not limited to intravascular, intramuscular, subcutaneous, inhalation, oral, rectal, transdermal or intra-nasal administration
• Polypeptide A polymer in which the monomers are amino acid residues which are joined together through amide bonds. When the amino acids are alpha- amino acids, either the L-optical isomer or the D-optical isomer can be used, the L- isomers being preferred.
• polypeptide or protein as used herein are intended to encompass any amino acid sequence and include modified sequences such as glycoproteins.
• polypeptide is specifically intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically produced.
• polypeptide fragment refers to a portion of a polypeptide, for example such a fragment which exhibits at least one useful sequence in binding a receptor.
• polypeptide refers to all fragments of a polypeptide that retain an activity of the polypeptide.
• Biologically functional peptides can also include fusion proteins, in which the peptide of interest has been fused to another peptide that does not decrease its desired activity.
• PYY A peptide YY polypeptide obtained or derived from any species.
• PYY includes the human full length polypeptide (as set forth in SEQ ID NO: 1) and species variations of PYY, including e.g. murine, hamster, chicken, bovine, rat, and dog PYY (SEQ ID NOS: 5-12).
• PYY agonists do not include NPY.
• PYY also includes PYY 3 . 36 .
• a "PYY agonist" is any compound which binds to a receptor that specifically binds PYY, and elicits an effect of PYY.
• a PYY agonist is a compound that affects food intake, caloric intake, or appetite, and or which binds specifically in a Y receptor assay or competes for binding with PYY, such as in a competitive binding assay with labeled PYY.
• PYY agonists include, but are not limited to, compounds that bind to the Y2 receptor.
• Substantially purified A polypeptide which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated.
• the polypeptide may be at least 50%, 80% or 90% free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated.
• Therapeutically effective amount A dose sufficient to prevent advancement, or to cause regression of a disorder, or which is capable of relieving a sign or symptom of a disorder, or which is capable of achieving a desired result, h several embodiments, a therapeutically effect of PYY or an agonist thereof is an amount sufficient to inhibit or halt weight gain, or an amount sufficient to decrease appetite, or an amount sufficient to reduce caloric intake or food intake or increase energy expenditure.
• a method for reducing food intake by peripherally administering to a subject a therapeutically effective amount of PYY or an agonist of PYY and GLP-1 or an agonist thereof results in a decrease in the amount, either the total weight or the total volume of food.
• administration of PYY, or an agonist thereof, and GLP-1 or an agonist thereof results in a decrease of the intake of a food component, such as a decrease in the ingestion of lipids, carbohydrates, cholesterol, or proteins.
• a preferred compound, PYY 3 . 36 can be administered.
• This disclosure includes the corresponding uses of PYY or an agonist thereof and GLP-1 or an agonist thereof, for the manufacture of a medicament or medicaments for the purposes set herein, and includes the use of PYY 3 . 36 .
• a method is also disclosed herein for reducing caloric intake by peripherally administering to a subject a therapeutically effective amount of PYY or an agonist of PYY and GLP-1 or an agonist thereof.
• total caloric intake is reduced by peripheral administration of a therapeutically effective amount of PYY and GLP-1 or an agonist thereof.
• the caloric intake from the ingestion of a specific food component such as, but not limited to, the ingestion of lipids, carbohydrates, cholesterol, or proteins, is reduced.
• a method for reducing appetite by administering a therapeutically effective amount of PYY or an agonist thereof and GLP-1 or an agonist thereof.
• Appetite can be measured by any means known to one of skill in the art.
• decreased appetite can be assessed by a psychological assessment.
• administration of PYY and the other agent(s) results in a change in perceived hunger, satiety, and/or fullness.
• Hunger can be assessed by any means known to one of skill in the art.
• hunger is assessed using psychological assays, such as by an assessment of hunger feelings and sensory perception using a questionnaire, such as, but not limited to, a Visual Analog Score (VAS) questionnaire (see the Examples section).
• VAS Visual Analog Score
• hunger is assessed by answering questions relating to desire for food, drink, prospective food consumption, nausea, and perceptions relating to smell or taste.
• a method for altering energy metabolism in a subject.
• the method includes peripherally administering a therapeutically effective amount of PYY or an agonist thereof and GLP-1 or an agonist thereof, to the subject, thereby altering energy expenditure.
• Energy is burned in all physiological processes.
• the body can alter the rate of energy expenditure directly, by modulating the efficiency of those processes, or changing the number and nature of processes that are occurring. For example, during digestion the body expends energy moving food through the bowel, and digesting food, and within cells, the efficiency of cellular metabolism can be altered to produce more or less heat.
• a method is disclosed herein for any and all manipulations of the arcuate circuitry described in this application, that alter food intake coordinately and reciprocally alter energy expenditure.
• PYY e.g., PYY 3 .
• the disclosure further relates to the use of PYY or an agonist and GLP-1 or an agonist thereof, in control of any one or more of appetite, satiety and hunger, in particular any one or more of the following: reducing, suppressing and inhibiting appetite; inducing, increasing, enhancing and promoting satiety and sensations of satiety; and reducing, inhibiting and suppressing hunger and sensations of hunger.
• the disclosure further relates to the use of PYY an agonist thereof and GLP-1 or an agonist thereof, in maintaining any one or more of a desired body weight, a desired Body Mass Index, a desired appearance and good health.
• the subject can be any subject, including both human and veterinary mammalian subjects.
• the subject can be a human, or can be a non-human primate, a farm animal such as swine, cattle, and poultry, a sport animal or pet such as dogs, cats, horses, hamsters, rodents, or a zoo animal such as lions, tigers, or bears.
• Obesity is currently a poorly treatable, chronic, essentially intractable metabolic disorder.
• a therapeutic drug useful in weight reduction of obese persons could have a profound beneficial effect on their health.
• the subject can be, but is not limited to, a subject who is overweight or obese.
• the subject has, or is at risk of having, a disorder wherein obesity or being overweight is a risk factor for the disorder.
• disorders of interest include, but are not limited to, cardiovascular disease, (including, but not limited to, hypertension, atherosclerosis, congestive heart failure, and dyslipidemia), stroke, gallbladder disease, osteoarthritis, sleep apnea, reproductive disorders such as, but not limited to, polycystic ovarian syndrome, cancers (e.g., breast, prostate, colon, endometrial, kidney, and esophagus cancer), varicose veins, acnthosis nigricans, eczema, exercise intolerance, insulin resistance, hypertension hypercholesterolemia, cholithiasis, osteoarthritis, orthopedic injury, insulin resistance (such as, but not limited to, type 2 diabetes and syndrome X) and tromboembolic disease (see Kopelman, Nature 404:635-43; Rissanen et al., British Med. J. 301, 835, 1990).
• cardiovascular disease including, but not limited to, hypertension, atherosclerosis,
• Obesity is a recognized risk factor for increased incidence of complications of general anesthesia. (See e. g.,
• condition or disorder which can be alleviated by reducing caloric (or nutrient) availability it is meant any condition or disorder in a subject that is either caused by, complicated by, or aggravated by a relatively high nutrient availability, or that can be alleviated by reducing nutrient availability, for example by decreasing food intake.
• Subjects who are insulin resistant, glucose intolerant, or have any form of diabetes mellitus (e.g., type 1, 2 or gestational diabetes) can also benefit from this disclosure.
• Such conditions or disorders are disorders associated with increased caloric intake, insulin resistance, or glucose intolerance and include, but are not limited to, obesity, diabetes, including type 2 diabetes, eating disorders, insulin-resistance syndromes, and Alzheimer's disease. '
• the subject is a subject who desires weight loss, such as female and male subject who desire a change in their appearance.
• the subject is a subject who desires decreased feelings of hunger, such as, but not limited to, a person involved in a lengthy task that requires a high level of concentration (e.g., soldiers on active duty, air traffic controllers, or truck drivers on long distance routes, etc.).
• a suitable administration format may be best determined by the subject or by a medical practitioner.
• the pharmaceutical compositions that include PYY, or an agonist thereof will preferably be formulated in unit dosage form, suitable for individual administration of precise dosages.
• An effective amount of PYY or an agonist thereof can be administered in a single dose, or in multiple doses, for example daily, during a course of treatment.
• PYY is administered whenever the effect (e.g., appetite suppression, decreased food intake, or decreased caloric intake) is desired.
• PYY or an analog thereof is administered slightly prior to whenever the effect is desired, such as, but not limited to about 10 minutes, about 15 minutes, about 30 minutes, about 60 minutes, about 90 minutes, or about 120 minutes, prior to the time the effect is desired.
• a time release formulation is utilized.
• a therapeutically effective amount of PYY or an agonist thereof is administered as a single pulse dose, as a bolus dose, or as pulse doses administered over time.
• pulse doses a bolus administration of PYY is provided, followed by a time period wherein no PYY is administered to the subject, followed by a second bolus administration.
• pulse doses of PYY are administered during the course of a day, during the course of a week, or during the course of a month.
• the therapeutically effective amount of PYY or an agonist thereof will be dependent on the molecule utilized, the subject being treated, the severity and type of the affliction, and the manner of administration.
• a therapeutically effective amount of PYY or an agonist thereof can vary from about 0.01 ⁇ g per kilogram (kg) body weight to about 1 g per kg body weight, such as about 1 ⁇ g to about 5 mg per kg body weight, or about 5 ⁇ g to about 1 mg per kg body weight.
• PYY or an agonist thereof is administered to a subject at 0.5 to 135 picomole (pmol) per kg body weight, or about 72 pmol per kg body weight.
• nmol is administered as a subcutaneous injection, such as about 2 to about 20 nmol, or about 10 nmol is administered as a subcutaneous injection.
• the exact dose is readily determined by one of skill in the art based on the potency of the specific compound (such as the PYY polypeptide, or agonist) utilized, the age, weight, sex and physiological condition of the subject.
• the dose of an agonist can be a molar equivalent of the therapeutically effective dose of PYY or PYY 3 . 36 .
• compositions or pharmaceutical compositions can be administered by any route, including intravenous, intraperitoneal, subcutaneous, sublingual, transdermal, intramuscular, oral, topical, transmucosal, or by pulmonary inhalation.
• Compositions useful in the disclosure may conveniently be provided in the form of formulations suitable for parenteral (including intravenous, intramuscular and subcutaneous), nasal or oral administration.
• parenteral refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
• PYY including PYY 3 . 36 , an agonist of PYY, or an antagonist of PYY, can be administered subcutaneously. It is well known in the art that subcutaneous inj ections can be easily self-administered.
• a PYY or a PYY agonist and another food-intake-reducing, plasma glucose-lowering or plasma lipid-altering agent in a single composition or solution for administration together.
• a suitable administration format may best be determined by a medical practitioner for each patient individually.
• Various pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E. W. Martin. See also Wang, Y. J. and Hanson, M. A., Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S, 1988.
• PYY and PYY agonists useful in the methods of this disclosure can be provided as parenteral compositions, e.g., for injection or infusion.
• they are suspended in an aqueous carrier, for example, in an isotonic buffer solution at a pH of about 3.0 to about 8.0, preferably at a pH of about 3.5 to about 7.4, 3.5 to 6.0, or 3.5 to about 5.0.
• Useful buffers include sodium citrate-citric acid and sodium phosphate-phosphoric acid, and sodium acetate/acetic acid buffers.
• a form of repository or "depot" slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal injection or delivery.
• the PYY and agonists are amphoteric, they may be utilized as free bases, as acid addition salts or as metal salts.
• the salts must, of course, be pharmaceutically acceptable, and these will include metal salts, particularly alkali and alkaline earth metal salts, e.g., potassium or sodium salts.
• metal salts particularly alkali and alkaline earth metal salts, e.g., potassium or sodium salts.
• a wide variety of pharmaceutically acceptable acid addition salts are available. Such products are readily prepared by procedures well known to those skilled in the art.
• the compositions can be provided in dosage unit form containing an amount of a PYY or a PYY agonist with or without another active ingredient, e.g., a food intake-reducing, plasma glucose-lowering or plasma lipid-altering agent.
• Administration may begin whenever the suppression of nutrient availability, food intake, weight, blood glucose or plasma lipid lowering is desired, for example, at the first sign of symptoms of a weight-related disorder or shortly
• Therapeutically effective amounts of a PYY or a PYY agonist for use in reducing nutrient availability are those that suppress appetite at a desired level.
• an effective amount of therapeutic agent will vary with many factors including the potency of the particular compound, age and weight of the patient, the patient's physical condition, the blood sugar level, the weight level to be obtained, and other factors.
• an effective amount of this therapeutic agent will also vary with many factors including the potency of the particular compound, age and weight of the patient, the patient's physical condition, the blood sugar level, the weight level to be obtained, and other factors.
• Administration may begin whenever the increased of nutrient availability, food intake, weight, blood glucose or plasma lipid lowering is desired, such as, but not limited to, at the first sign of symptoms of a anorexia or at the onset of weight loss due to ADDS.
• the optimal formulation and mode of administration of PYY or a PYY agonist to a patient depend on factors known in the art such as the particular disease or disorder, the desired effect, and the type of patient. While the PYY and PYY agonists will typically be used to treat human subjects they may also be used to treat similar or identical diseases in other vertebrates such as other primates, farm animals such as swine, cattle and poultry, and sport animals and pets such as horses, dogs and cats.
• PYY and PYY agonists of the present disclosure may be administered directly by any suitable technique, including parenterally, intranasally, orally, or by absorption through the skin.
• the specific route of administration of each agent will depend, e.g., on the medical history of the animal.
• PYY and PYY agonists can be formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
• “Pharmaceutically acceptable carrier” refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
• the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to PYY and PYY agonists.
• the formulations are prepared by contacting the PYY or PYY agonist uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation.
• the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.
• PPY and PYY agonists are also suitably administered by sustained-release systems.
• sustained-release PYY and PYY agonists include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).
• Sustained-release PPY and PYY agomst compositions may be administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray.
• Sustained release matrices include polylactides (U.S. Patent No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., Biopolymers 22:541-556, 1983, poly(2-hydroxyethyl methacrylate)); (Langer et al., J. Biomed. Mater. Res.15:167-277, 1981; Langer, Chem. Tech. 12:98-105, 1982, ethylene vinyl acetate (Langer et al., Id.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988).
• polylactides U.S. Patent No. 3,773,919, EP 58,481
• copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., Biopolymers 22
• Sustained-release PPY and PYY agonists include liposomally PPY and PYY agonists (see generally, Langer, Science 249:1527-1533, 1990; Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317-327 and 353-365, 1989).
• Liposomes containing PPY peptide and peptide analogs are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. U.S.A. 82:3688-3692, 1985; Hwang et al., Proc.
• the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mole percent cholesterol, the selected proportion being adjusted for the optimal performance.
• the pharmaceutical compositions may be in the form of particles comprising a biodegradable polymer and/or a polysaccharide jellifying and or bioadhesive polymer, an amphiphilic polymer, an agent modifying the interface properties of the particles and a pharmacologically active substance.
• these compositions exhibit certain biocompatibility features which allow a controlled release of the active substance. See U.S. Patent No. 5,700,486.
• PPY and PYY agonists are delivered by way of a pump (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng.
• PPY and PYY agonists are delivered by way of an implanted pump, described, for example, in U.S. Patent No. 6,436,091; U.S. Patent No. 5,939,380; U.S. Patent No. 5,993,414.
• Implantable drug infusion devices are used to provide patients with a constant and long term dosage or infusion of a drug or any other therapeutic agent. Essentially such device may be categorized as either active or passive.
• Active drug or programmable infusion devices feature a pump or a metering system to deliver the drug into the patient's system.
• An example of such an active drug infusion device currently available is the Medtronic SynchroMedTM programmable pump.
• Such pumps typically include a drug reservoir, a peristaltic pump to pump out the drug from the reservoir, and a catheter port to transport the pumped out drug from the reservoir via the pump to a patient's anatomy.
• Such devices also typically include a battery to power the pump as well as an electronic module to control the flow rate of the pump.
• the Medtronic SynchroMedTM pump further includes an antenna to permit the remote programming of the pump. Passive drug infusion devices, in contrast, do not feature a pump, but rather rely upon a pressurized drug reservoir to deliver the drug.
• Such devices tend to be both smaller as well as cheaper as compared to active devices.
• An example of such a device includes the Medtronic IsoMedTM. This device delivers the drug into the patient through the force provided by a pressurized reservoir applied across a flow control unit.
• the implanted pump can be completely implanted under the skin of a patient, thereby negating the need for a percutaneous catheter.
• These implanted pumps can provide the patient with PYY or a PYY agonist at a constant or a programmed delivery rate, e.g., to give pulsed doses at or around meal time.
• Constant rate or programmable rate pumps are based on either phase-change or peristaltic technology. When a constant, unchanging delivery rate is required, a constant-rate pump is well suited for long-term implanted drug delivery. If changes to the infusion rate are expected, a programmable pump may be used in place of the constant rate pump system. Osmotic pumps may be much smaller than other constant rate or programmable pumps, because their infusion rate can be very low. An example of such a pump is described listed in U.S. Patent No. 5,728,396.
• the pharmaceutical compositions can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate).
• binding agents e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
• fillers e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate
• lubricants e.g., magnesium stearate, talc or silica
• disintegrants e.g., potato starch
• Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use.
• Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p- hydroxybenzoates or sorbic acid).
• suspending agents e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats
• emulsifying agents e.g., lecithin or acacia
• non-aqueous vehicles e.g., almond oil, oily esters, eth
• the preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
• the compounds for use according to the present disclosure are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromemane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
• a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromemane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
• a pressurized aerosol the dosage unit can be determined by providing a valve to deliver a metered amount.
• Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lac
• the compounds can also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
• the compounds can also be formulated as a depot preparation.
• Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
• the compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
• compositions that comprise a PYY, or an agonist thereof, as described herein as an active ingredient will normally be formulated with an appropriate solid or liquid carrier, depending upon the particular mode of administration chosen.
• the pharmaceutically acceptable carriers and excipients useful in this disclosure are conventional.
• parenteral formulations usually comprise injectable fluids that are pharmaceutically and physiologically acceptable fluid vehicles such as water, physiological saline, other balanced salt solutions, aqueous dextrose, glycerol or the like.
• Excipients that can be included are, for instance, other proteins, such as human serum albumin or plasma preparations.
• the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
• auxiliary substances such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
• Other medicinal and pharmaceutical agents for instance other appetite suppressants, or protease inhibitors, also may be included. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art.
• the dosage form of the pharmaceutical composition will be determined by the mode of administration chosen.
• the pharmaceutical compositions can be produced of conventional mixing, granulating, confectioning, dissolving or lyophilizing processes.
• Oral formulations maybe liquid (e.g., syrups, solutions or suspensions), or solid (e.g., powders, pills, tablets, or capsules).
• pharmaceutical compositions for oral use can be obtained by combining the active ingredient with one or more solid carriers, optionally granulating a resulting mixture, and, if desired, processing the mixture or granules, if appropriate with the addition of additional excipients, to form tablets or dragee cores.
• Suitable carriers include fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, also binders, such as starches, for example corn, wheat, rice or potato starch, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyffolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, also carboxymethyl starch, cross-linked polyvinylpyrrolidone, alginic acid or a salt thereof, such as sodium alginate.
• Additional excipients include flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol, or derivatives thereof.
• compositions include suitable aqueous solutions of an active ingredient in water-soluble form, for example in the form of a water-soluble salt, or aqueous injection suspensions that contain viscosity-altering substances, for example sodium carboxymethylcellulose, sorbitol and or dextran, and, if desired, stabilizers.
• the active ingredient optionally together with excipients, can also be in the form of a lyophilisate and can be made into a solution prior to parenteral administration by the addition of suitable solvents. Solutions such as those that are used, for example, for parenteral administration can also be used as infusion solutions.
• PYY or an agonist thereof is administered as an aerosol or a dispersion in a carrier.
• PYY or an agonist thereof is administered as an aerosol from a conventional valve, such as, but not limited to, a metered dose valve, through an aerosol adapter also known as an actuator.
• a suitable fluid carrier can be also included in the formulation, such as, but not limited to, air, a hydrocarbon, such as n-butane, propane, isopentane, amongst others, or a propellant, such as, but not limited to a fluorocarbon.
• a stabilizer is also included, and/or porous particles for deep lung delivery are included (e.g., see U.S. Patent No. 6,447,743).
• an inhalation formulation for a sustained release includes using aerosol droplet particles approximately 1-2.1 ⁇ m in size, or of less than 1 ⁇ m in size. Small particle aerosol liposomes and liposome-drug combinations for medical use have been previously described (e.g., see EP 87309854.5).
• a therapeutically effective amount of PYY or an agonist thereof is administered with a therapeutically effective amount of GLP-1 or an agonist thereof.
• the PYY or agonist thereof and the GLP-1 or an agonist thereof may be administered simultaneously or substantially simultaneously, or sequentially, in any order.
• the PYY or agonist thereof and the GLP-1 or an agonist thereof may be administered in a single pharmaceutical composition or in separate compositions, and they may be administered by the same route or my different routes.
• the PYY and the GLP-1 or an agonist thereof are to be administered in a single pharmaceutical composition
• that composition may be any of those described above for PYY or an agonist thereof.
• the composition may enable simultaneous or substantially simultaneous administration of the PYY or agonist thereof and the GLP-1 or an agonist thereof.
• the PYY or agonist thereof and the GLP-1 or an agonist thereof may be compartmentalized in the composition, for example, in different layers of a tablet, or in different granules in a capsule. If desired, such compartmentalization may be designed to give different release properties to the two components to enable delivery of the PYY or agonist component and the GLP-1 or an agonist thereof at different times, for example, sequentially.
• the PYY or agonist thereof and the GLP-1 or an agonist thereof may be formulated in separate pharmaceutical compositions, for example, any of the pharmaceutical compositions described above for PYY and agonists thereof.
• Such separate compositions may be administered simultaneously or substantially simultaneously, or they may be administered sequentially, in any order.
• the PYY or agonist thereof and the GLP-1 or an agonist thereof may be administered by the same route or by different routes. It is generally more convenient to administer all the active agents in a single composition. However, in some cases it may be necessary or appropriate to administer the active agents by different routes. For example, peptides are generally not stable on oral administration unless modified or formulated in a special way, so must generally be administered via a non-oral route. Some agonists, for example, GLP-1 agonists, are chemical compounds that are stable when administered orally. It may be appropriate to administer OXM non-orally and the other component by a non-oral route.
• the medicament may be a single pharmaceutical composition comprising both components, as described above, or may be a two-component medicament, one component being a pharmaceutical composition comprising PYY or an agonist thereof, the other component being a pharmaceutical composition comprising GLP-1 or an agonist thereof, see above.
• the medicament whether a one component medicament or a two component medicament as described above, will generally be packaged with instructions relating to its use. Such instructions will refer to the timing, dose and route of administration of the component(s) .
• a further agent that influences food intake and/or appetite may also be administered.
• agents include naturally-occurring agents and agonists thereof, for example, amylin and amylin agonists, leptin and leptin agonosts, and oxyntomodulin.
• one or more other agents such as, but not limited to, an additional appetite suppressant, may also be administered.
• an additional appetite suppressant include amfepramone (diethylpropion), phentermine, mazindol and phenylpropanolamine, fenfluramine, dexfenfluramine, and fluoxetine.
• PYY or a PYY agonist, or GLP-1 or a GLP-1 agonist, or both can be administered simultaneously with the additional agent(s), or the various substances may be administered sequentially, and in any order.
• PYY or an agonist thereof and GLP-1 or an agonist thereof is formulated and administered with an additional agent, for example, oxyntomodulin or an agonist thereof, or an appetite suppressant as a single composition.
• a method of treating obesity includes administering to an obese subject a therapeutically effective amount of PYY or a PYY agonist, and GLP-1 or an agonist thereof.
• the PYY agonist can have potency in at least one of food intake or gastric emptying greater than NPY.
• PYY or a PYY agonist can be administered peripherally, such as in a single or divided dose. Suitable single or divided doses include, but are not limited to, 1 ⁇ g to about 5 mg or about 0.01 ⁇ g/kg to about 500 ⁇ g/kg per dose.
• the subject can be insulin resistant or glucose intolerant, or both. In addition to being obese, the subject can have diabetes mellitus.
• a method of reducing food intake includes administering to an obese subject a therapeutically effective amount of PYY or a PYY agonist, and GLP-1 or an agonist thereof.
• the PYY agonist can have potency in at least one of food intake or gastric emptying greater than NPY.
• PYY or a PYY agonist can be administered peripherally, such as in a single or divided dose. Suitable single or divided doses include, but are not limited to, 1 ⁇ g to about 5 mg or about 0.01 ⁇ g/kg to about 500 ⁇ g/kg per dose.
• the subject can have -Type JJ diabetes, and/or can be overweight.
• a method for improving lipid profile in a subject includes administering to the subject an effective amount of PYY or a PYY agonist, and GLP-1 or an agonist thereof.
• An improvement in lipid profile includes, but is not limited to, at least one method of reducing cholesterol levels, reducing triglyceride levels and increasing HDL cholesterol levels.
• PYY or a PYY agonist can be administered peripherally, such as in a single or divided dose.
• PYY or a PYY agonist can be administered peripherally, such as in a single or divided dose. Suitable single or divided doses include, but are not limited to, 1 ⁇ g to about 5 mg or about 0.01 ⁇ g/kg to about 500 ⁇ g/kg per dose.
• the PYY agonist can have potency in at least one of food intake or gastric emptying greater than NPY.
• a method for alleviating a condition or disorder which can be alleviated by reducing nutrient availability.
• the method includes administering to a subject a therapeutically effective amount of PYY or a PYY agonist, and GLP-1 or an agonist thereof.
• Suitable disorders include any of the disorders mentioned above.
• the PYY or a PYY agonist and GLP-1 or GLP-1 agonist can be administered peripherally, such as in a single or divided dose.
• Suitable single or divided doses include, but are not limited to, 1 ⁇ g to about 5 mg or about 0.01 ⁇ g/kg to about 500 ⁇ g/kg of PYY or a PYY agonist per dose.
• the PYY agonist can have potency in at least one of food intake or gastric emptying greater than NPY.
• Suitable doses also include those that raise the concentration of PYY and/or the agonist thereof significantly above the basal concentration of PYY, such as, but not limited to, a dose that that mimic postparandial serum concentrations of PYY (or the agonist).
• PYY or an agonist thereof is administered to achieve the level of to effect a reduction in calorie intake, food intake, or appetite equivalent to the reduction in calorie intake, food intake, or appetite, or to increase the energy expenditure, caused by the postprandial level of PYY 3 . 36 .
• doses include, but are not limited doses that produce the effect demonstrated when the serum levels of PYY are from about 40 pM/litre to about 60 pM/litre, for example, from about 40 pM/litre to about 50 pM/litre, or from about 40 pM/litre to about 45 pM/litre, or to about 43 pM/litre.
• the dose of PYY or PYY 3 . 36 can be based on the physiological levels observed post-prandially.
• the normal circulating levels of PYY 3 . 36 are about 8 pmol/litre, typically rising to about 40 to 60 pmol litre after a meal.
• Agonists of PYY can be used at analogous doses.
• a single dose may be administered per day, or divided doses can be used (see above).
• PYY 3 . 36 has a prolonged and sustained action, continuing to act even after it has been cleared from the circulating blood, for example, for up to 12 and even up to 24 hours. Accordingly, PYY or an agonist thereof may be administered twice per day or even just once.
• more doses may be administered, for example, three or four per day.
• PYY or an agonist thereof before a meal, for example, about half an hour before a meal.
• PYY or an agonist thereof before each meal.
• GLP-1 or an agonist may be administered according to the same regime as the PYY or agonist thereof, whether administered simultaneously or substantially simultaneously with the PYY or PYY agonist, or sequentially.
• the GLP-1 may be administered in a different regime, for example, with more doses of GLP-1 than of PYY, for example, the PYY or PYY agonist may be administered once or twice per day, and the GLP-1 or agonist thereof may be administered three or four times per day.
• PYY or a PYY agonist may be administered in the morning and evening, for example, before breakfast and before the evening meal, and the GLP-1 agonist thereof may also be administered before the mid-day meal.
• PYY including
• PYY 3 . 3 6 has its effects at physiological levels. No side effects are observed when PYY 3 . 36 is used at such levels. Without being bound by theory, PYY 3 . 36 does not affect Y2 receptors throughout the brain, which could cause side effects. It should be noted, without being limiting, that a further advantage of PYY 3 . 36 is that PYY 3 . 36 does not increase blood pressure. The effects of PYY 3 . 36 are as long lasting as 24 hours. Recipients claim a decrease in appetite over that period, and a reduction of food intake of about one third has been reported.
• PYY 3 . 36 is administered in a dose of about 1 nmol or more, 2 nmol or more, or 5 nmol or more.
• the dose of PYY 3 . 36 is generally not more than 100 nmol, for example, the dose is 90 nmols or less, 80 nmols or less, 70 nmols or less, 60 nmols or less, 50 nmols or less, 40 nmols or less, 30 nmols or less, 20 nmols or less, 10 nmols.
• a dosage range may comprise any combination of any of the specified lower dose limits with any of the specified upper dose limits.
• exemplar non-limiting dose ranges include a dose of PYY 3 . 36 may be within the range of form 1 to 100 n mols, from 1 to 90 mols, from 1 to 80 nmols.
• exemplary, non-limiting dose ranges include, from 2 to 100 nmols, from 2 to 90 n mols, for example, from 2 to 80 nmols etc., from 5 nmols to 100 mols, from 5 nmols to 90 nmols, from 5 nmols to 80 nmols etc.
• a dose of from about 5 to about 50 nmol may be administered such as, but not limited to, from about 2 to about 20 nmol, for example, about 10 nmol.
• the selected dose may be administered for example, by injection, for example, as a subcutaneous injection.
• a PYY agonist may be administered at the same dose.
• PYY 3 . 36 may be administered peripherally at a dose of 0.1 nmoles or more per kg body weight of the subject, for example, 0.2 nmoles or more, for example, 0.4 nmoles or more, for example, 0.6 nmoles or more, for example, 0.8 nmoles or more, for example, 1.0 nmole or more, for example, 1.2 nmoles or more, for example, 1.4 nmoles or more, for example, 1.6 nmoles or more, for example, 1.8 nmoles or more, for example, 2.0 nmoles or more, for example, 2.2 nmoles or more, for example, 2.4 nmoles or more, for example, 2.6 nmoles or more, for example, 2.8 nmoles, for example, 3.0 nmoles or more, for example, up to 3.2 nmoles per kg body weight.
• PYY 3 . 36 or a PYY agonist andmay be administered peripherally in an amount of up to 3.0 nmoles per kg body weight, for example, up to 2.8 nmoles, for example, up to 2.6 nmoles, for example, up to 2.4 nmoles, for example, up to 2.2 nmoles, for example, up to 2.0 nmoles, for example, up to 1.8 nmoles, for example, up to 1.4 nmoles, for example, up to 1.2 nmoles, for example, up to 1.0 nmoles, for example, up to 0.8 nmoles, for example, up to 0.6 nmoles, for example, up to 0.4 nmoles, for example, up to 0.2 nmoles per kg body weight.
• up to 3.0 nmoles per kg body weight for example, up to 2.8 nmoles, for example, up to 2.6 nmoles, for example
• a dose of PYY for example PYY 3 . 36 or a " PYY agonist of 10 nmoles or more, for example, 20 nmoles or more, for example, 30 nmoles or more, for example, 40 nmoles or more may be used. It is generally preferable to use up to about 70 nmoles, for example, up to about 60 nnmoles. A dose of about 40nmoles may be used.
• a dose of PYY or PYY 3 . 36 at 0.143 n moles (l/7 th of a mole) is administered per kilogram, to achieve a dose that is similar to the postprandial level of PYY.
• the dose is preferably a molar equivalent of a PYY 3 . 36 dose, or achieves the same effect as a PYY 3 .36 dose, as described above.
• the doses can be calculated on the basis of a subject, such as a subject weighing from 70 to 75 kg. The exact dose is readily determined by one of skill in the art based on the potency of the specific compound (such as the PYY polypeptide, or agonist) utilized, and the age, weight, sex and physiological condition of the subject. All the teachings given above in relation to PYY 3 . 36 also apply to PYY itself and to PYY agonists. For example, the teachings relating to routes of administration and dosage regimes.
• GLP-1 or an agonist thereof should be administered in an therapeutically effective dose, see the section relating to GLP-1 and agonists thereof below.
• GLP-1 or an agonist thereof may be used in amounts or doses in the ranges described above for PYY or a PYY agonist.
• the doses of the various agent may be independent of each other or, for example, equimolar doses may be used, for example, equimolar doses of GLP-1 or an agonist thereof and PYY or an agonist thereof.
• a naturally occurring peptide, PYY or PYY 3 . 36 can be used to achieve a physiological effect. This results in minimal side effects and enables long term use, if necessary.
• the dose of PYY or PYY 3 . 36 can be based on the physiological levels observed post-prandially.
• the normal circulating levels of PYY 3 . 36 are about 8 pmol litre, typically rising to about 40 to 60 pmol litre after a meal.
• PYY (e.g., PYY 3 . 36 ) and agonists can be used at analogous doses.
• the considerations set out above in relation to the administration regime also relate to a ⁇ iiinistration using the subcutaneous route.
• PYY e.g., PYY 3 . 36
• GLP-1 GLP-1 or an agonist thereof
• Some of the treatments described above are medical treatments, for example, the treatment of obesity. Others, however, do not relate to medical treatment, and are part of the maintenance of a healthy lifestyle, or are for cosmetic purposes.
• any of OXM and GLP-1 or an agonist thereof and PYY or an agonist thereof may serve to increase the effectiveness of any of the agents compared with its use alone, for example, as described above.
• use of the two or three agents in combination may reduce any tendency for "escape" when using an agent alone.
• the term "escape” is used to denote a reduction in effect of an agent with time. For example, if any one of the agents above has been used alone, its effect may reduce with time.
• Use of one or both of the other agents in addition may reduce or prevent the tendency for that reduction in effectiveness.
• PYY has a sustained effect and may be used for prolonged periods. If the effect of PYY should appear to reduce, or to reduce or prevent any such reduction in effect, OXM may be administered in addition to the PYY.
• GLP-1 may also be used for the same purpose, with OXM or with OXM and PYY.
• the present invention provides a pharmaceutical composition that comprises PYY or a PYY agonist as the active ingredient and a pharmaceutically suitable carrier in a form suitable for subcutaneous admimstration, for example, as an injectable solution.
• a composition may comprise an amount of PYY for example PYY 3 . 36 or a PYY agonist of 10 nmoles or more, for example, 20 nmoles or more, for example, 30 nmoles or more, for example, 40 nmoles or more may be used. It is generally preferable to use up to about 70 nmoles, for example, up to about 60 nnmoles. An amount of about 40nmoles may present..
• Suitable formulations for subcutaneous administration are well known, and are described above.
• One or more further active ingredient(s) may also be present in the composition, in particular GLP-1 or an agonist thereof, which may be used in amounts and doses as described above.
• Further active ingredients may be present, for example, as described above, for example, oxyntomodulin or an agonist thereof, or an appetite suppressant as described above.
• a further aspect of the invention relates to methods as disclosed above, including a method for decreasing calorie intake in a subject, a method for decreasing appetite in a subject, a method for decreasing food intake in a subject, a method for weight control or treatment in a subject, and a method for reduction or prevention of obesity, in particular any one or more of the following: preventing and reducing weight gain; inducing and promoting weight loss; and reducing obesity as measured by the Body Mass Index.
• the methods include control of any one or more of appetite, satiety and hunger, in particular any one or more of the following: reducing, suppressing and inhibiting appetite; inducing, increasing, enhancing and promoting satiety and sensations of satiety; and reducing, inhibiting and suppressing hunger and sensations of hunger.
• the methods further include maintaining any one or more of a desired body weight, a desired Body Mass Index, a desired appearance and good health.
• PYY for example, PYY 3 . 36 or a PYY agonist is administered subcutaneously to the subject.
• the PYY or PYY agonist is administered at dose of 10 nmoles or more, for example, 20 nmoles or more, for example, 30 nmoles or more, for example, 40 nmoles or more may be used. It is generally preferable to use up to about 70 nmoles, for example, up to about 60 nnmoles. An dose of about 40nmoles be used.
• PYY 3 . 36 has a prolonged and sustained action, continuing to act even after it has been cleared from the circulating blood, for example, for up to 12 and even up to 24 hours. Accordingly, PYY or an agonist thereof may be administered twice per day or even just once.
• more doses may be administered, for example, three or four per day.
• PYY or an agonist thereof before a meal, for example, about half an hour before a meal.
• PYY or an agonist thereof before each meal.
• PYY or an agonist thereof may be administered alone or PYY or an agonist thereof and GLP-1 or an agonist thereof may be administered.
• GLP-1 or an agonist thereof may be administered simultaneously or substantially simultaneously with the PYY or agonist thereof, or sequentially, in either order.
• the PYY or agonist thereof and the GLP-1 or agonist thereof may be administered in a single pharmaceutical composition or in separate compositions, and they may be administered by the same route or by different routes. Further active ingredients may also be administered, for example, as described above for subcutaneous PYY pharmaceutical compositions.
• the present invention also includes PYY or an agonist thereof for use in the manufacture of a medicament for subcutaneous administration for any of the methods of treatment described above.
• a PYY agonist of use in the methods of the present disclosure, is a molecule that binds to a receptor that specifically binds PYY, and elicits an effect of PYY.
• Assays for binding to PYY receptors, and eliciting a response in a cell with a PYY receptor, are known in the art.
• a specific assay for detecting a PYY agonist is also disclosed herein.
• a PYY agonist binds to a NPY neuron in the arcuate nucleus, which results in an electrophysiological effect on an NPY neuron.
• NPY neurons synapse with POMC neurons.
• an administration of PYY agonist results in hyperpolization of the membrane potential of a POMC neuron.
• administration of a PYY agonist results in an increase in IP SCs in a POMC neuron.
• PYY agonists do not include NPY.
• Suitable PYY agonists include molecules that bind NPY neurons, but do not cross the blood/brain barrier. The arcuate nucleus neurons upon which PYY exerts its effects are not protected by the blood/brain barrier, and thus are readily accessible to peripherally available molecules.
• a PYY agonist is a compound that affects food intake, caloric intake, or appetite, and/or which binds specifically in a Y receptor assay or competes for binding with PYY, such as in a competitive binding assay with labeled PYY.
• PYY agonists include, but are not limited to, compounds that bind to the Y2 receptor.
• PYY and agonists useful in the methods disclosed herein include, but are not limited to, polypeptides comprising, or alternatively consisting of, the amino acid sequence for PPY and agonists thereof, e.g., mutants, fragments and or variants thereof.
• Variants include deletions, insertions, inversions, repeats and substitutions (e.g., conservative substitutions and non-conservative substitutions; see, e.g., Tables 1 and 2, infra). More than one amino acid (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) can be deleted or inserted or substituted with another amino acid.
• conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and He; interchange of Ser and Thr containing hydroxy residues, interchange of the acidic residues Asp and Glu, interchange between the amide residues Asn and Gin, interchange of the basic residues Lys and Arg, interchange of the aromatic residues Phe and Tyr, and interchange of the small-sized amino acids Ala, Ser, Thr, Met and Gly.
• Guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310, 1990.
• polypeptide fragments may contain a continuous series of deleted residues from the amino (N)- or the carboxyl (C)- terminus, or both (see, e.g., Tables 1 and 2, infra). Any number of amino acids, ranging from 1 to 24, can be deleted from the N-terminus, the C-terminus or both.
• the agonist polypeptides may also include, but are not limited to, polypeptides comprising, or alternatively consisting of, internal deletions of the amino acid sequences for PPY and/or agonist thereof (see, e.g., Table 2, infra). Such deletions may comprise one or more amino acid residue deletions (e.g., one, two, three, four, five, six, seven, eight, nine, ten, etc.) and may begin at any amino acid position (e.g., two, three, four, five, six, seven, eight, nine, ten, etc.).
• the polypeptides of this disclosure may contain one or more such internal deletions. Such deletions are contemplated in PPY, NPY and PP.
• agonist peptides that are PPY, NPY and or PP chimeras having high affinity and/or selectivity for the Y2 receptor.
• These chimeras may comprise amino acid substitutions of one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) from PPY, NPY and/or PP, variants, mutants and/or deletions thereof, with one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) from a second PPY, NPY, or PP, variants, mutations and/or deletions thereof.
• substitutions may begin at any amino acid position (e.g., two, three, four, five, six, seven, eight, nine, ten, etc.).
• the peptide is selective for the Y2 receptor. That is, it binds with higher affinity to Y2 compared to other receptors, such as Yl, Y2, Y3, Y4, Y5 and Y6. In another embodiment, the peptide is selective for the Y2 and Y5 receptors over the Yl, Y3, Y4 and Y6 receptors.
• Other polypeptide fragments are fragments comprising structural or functional domain of the polypeptides of this disclosure.
• Such fragments include amino acid residues that comprise a polyproline-type II helix (residues 1-8), beta- turn (residues 9-14), amphipathic alpha-helix (residues 15-32) and/or a C-terminal turn structure (residues 33-36). See, Kirby et al., JMed Chem 36:385-393, 1993.
• this disclosure includes the use of a polypeptide or agonist comprising, or alternatively consisting of, the amino acid sequence for PPY, NPY and PP species variants (see Table 1, infra) and/or mutants, and fragments thereof.
• fusion proteins whereby a PYY or PYY agonist will be fused to another protein or polypeptide (the fusion partner) using recombinant methods known in the art.
• a fusion protein may be synthetically synthesized by any known method. Any known peptide or protein can be used as the fusion partner (e.g., serum albumin, carbonic anhydrase, glutathione-S- transferase or thioredoxin, etc.).
• Preferred fusion partners will not have an adverse biological activity in vivo.
• Such fusion proteins may be designed linking the carboxy-terminus of the fusion partner to the amino-terminus of the PYY or agonist peptide, or vice versa.
• a cleavable linker region may be used linking the PYY or PYY agonist to the fusion partner, and may be cleaved in vivo thereby resulting in the release of an active form of PYY or a PYY agonist.
• cleavage regions include, but are not limited to, the linker regions D-D-D-D-Y (SEQ ID NO: 330), G-P-R (SEQ ID NO: 331), A-G-G (SEQ ID NO: 332) and H-P- F-H-L (SEQ ID NO 333), which can be cleaved by enterokinase, thrombin, ubiquitin cleaving enzyme and renin, respectfully.
• PYY agonists are Y2 specific NPY peptide agonists as described in U.S. Patent No. 5,026,685; U.S. Patent No. 5,574,010; U.S. Patent No. 5,604,203; U.S. Patent No. 5,696,093; U.S. Patent No. 6,046,167. See below:
• Preferred PPY agonists are described herein as follows.
• Rat YPAKPEAPGEDASPEELSRYYASLRHYLNLVTRQRY (SEQ ID NO: 5)
• Cow YPSKPDNPGEDAPAEDLARYYSALRHYINLITRQRY (SEQ ID NO: 17)
• Bullfrog APSEPHHPGDQATPDQLAQYYSDLYQYITFITRPRF (SEQ ID NO: 35) Ref: Beck-Sickinger, A.G., Jung, G., Biopolymers 37:123-142, 199,5.
• IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ID NO: 334) Ref Eberlein et al., Peptides 10:797-803, 1989; Grandt et al., Peptides 15(5):815- 20, 1994.
• YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY (SEQ ID NO: 2) Refi Tatemoto et al., Proc Natl Acad Sci U.S.A. 79:5485-9, 1982.
• N-Terminal Deletions of NPY including but not limited to: NPY(26-36), NPY(25- 36), NPY(24-36), NPY(23-36), NPY(22-36), NPY(21-36), NPY(20-36), NPY(19- 36), NPY(18-36), NPY(17-36), NPY(16-36), NPY(15-36), NPY(14-36), NPY(13- 36), NPY(12-36), NPY(ll-36), NPY(10-36), NPY(9-36), NPY(8-36), NPY(7-36), NPY(6-36), NPY(5-36), NPY(4-36), NPY(3-36).
• Cyclic agonist of NPY including but not limited to: [Lys 25-Glu 29]NPY(Ac-25- 36), [Glu 25-Lys 29]NPY(Ac-25-36), [Lys 26-Glu31]NPY(Ac-25-36), [Glu 27-Lys 3 l]NPY(Ac-25-36), [Lys28-Glu 32]NPY(Ac-25-36), [Lys27-Glu34]NPY(Ac-25- 36). Ref: Rist et al., EurJ Biochem 247:1019-1028, 1997.
• D-amino acid substitutions [D-Tyr ⁇ NPY, [D-Pro 2 ]NPY, [D-Ser 3 ]NPY, [D- Lys 4 ]NPY, [D-Pro 5 ]NPY, [D-Asp 6 ]NPY, [D-Asn 7 ]NPY, [D-Pro 8 ]NPY, [D- Ala 9 ]NPY, [D-Glu 10 ]NPY, [D-Asp n ]NPY, [D-Ala 12 ]NPY, [D-Pro 13 ]NPY, [D- Ala 14 ]NPY, [D-Glu 15 ]NPY, [D-Asp 16 ]NPY, [D-Leu 17 ]NPY, [D-Ala 18 ]NPY, [D- Arg 19 ]NPY, [D-Tyr 20 ]NPY, [D-Tyr ⁇ JNPY, [D-Se ⁇ JNPY, [D-Ala 23
• SKPDNPGEDAPAEDMARYYSALRHYINLITRQRY (SEQ ID NO: 335) Ref Grandt et al., Regulatory Peptides 67(l):33-7, 1996.
• PAEDLAQYAAELRHYLNLLTRQRY (SEQ ID NO: 216) Ref Potter et al., Eur J Pharmacol 267(3):253-262, May 17, 1994.
• SKPDNPGEDAPAEDMARCYSACRHYINLITRQRY (SEQ ID NO: 315) Ref Soil et al., Ear JR/oc/*er ⁇ 268(10):2828-37, May 2001.
• RHYLNLIGRQRY (SEQ ID NO: 316) Ref: Cabrele et al., JPept S 6(3):97-122, Mar 2000.
• RHGLNLLGRQRY (SEQ ID NO: 317) Ref Cabrele et al., JPept Sci 6(3):97-122, Mar 2000.
• N-Terminal Deletions including but not limited to: PP(26-36), PP(25-36), PP(24- 36), PP(23-36), PP(22-36), PP(21-36), PP(20-36), PP(19-36), PP(18-36), PP(17-36), PP(16-36), PP(15-36), PP(14-36), PP(13-36), PP(12-36), PP(ll-36), PP(10-36), PP(9-36), PP(8-36), PP(7-36), PP(6-36), PP(5-36), PP(4-36), PP(3-36).
• VYY(9-36) PEPTIDE SEQUENCE PYY(9-36) GEDASPEELNRYYASLRHYLNLVTRQRY (SEQ ED NO: 178)
• X is H or C a Me or N 3 Me or desamino or an acyl group having 7 carbon atoms or less;
• Q is R 1 -R 18 , R 18 or desQ;
• R 17 is Met, Arg, Nle, Nva, Leu, Ala or D-Ala;
• R 18 is Ala, Ser, He, D-Ala, D-Ser or D-Ile;
• R 19 is Arg, Lys or Gin;
• R 20 is Tyr or Phe;
• R 21 is Tyr, Glu, His or Ala;
• R 22 is Ser, Ala, Thr, Asn or Asp;
• R 23 is Ala, Asp, Glu, Gin, Asn or Ser;
• R 25 is Arg or Gin;
• R 26 is His, Arg or Gin;
• R2 is Phe or Tyr;
• R 28 is He, Leu, Val or Arg;
• R 29 is Asn or He;
• R 30 is Leu, Met, Thr or Na
• NPY neuropeptide Y
• potent postsynaptic treatment of hypertension and cardiogenic shock the treatment of acute cardiovascular circulatory failure
• the elevation of intracellular calcium See U.S. Patent No. 5,026,685.
• Certain preferred NPY analogs have the formula: X-R 18 -Arg-Tyr-Tyr-R 2 2-
• R 23 -Leu-Arg-His-Tyr-R 28 -Asn-Leu-R 3 ⁇ -Thr-Arg-Gln-Arg-Tyr-NH 2 , wherein X is H or C Me or N 3 Me or desamino or an acyl group having 7 carbon atoms or less; R 18 is Ala or Ser; R 22 is Ser or Ala; R 23 is Ala or Ser; R 27 is Phe or Tyr; R 28 is He or Leu; R 31 is He or Nal; and R 36 is Phe or Tyr; provided that at least one of R 27 and R 36 is Phe. See U.S. Patent No. 5,026,685.
• X is desamino or C a Me or N a Me and wherein R 18 , R 2 5, R27 and R 36 are as previously indicated.
• NPY agonists examples include:
• pNPY (17-36) having the formula: H-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln- Arg-Tyr-NH 2 (SEQ TD NO: 217)
• the peptide hNPY (17-36) having the formula: H-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-ne-Asn-Leu-Ile-Thr-Arg-Gln- Arg-Tyr-NH 2 (SEQ TD NO: 218)
• the peptide [Ac-D-Ala 17 ]-NPY (17-36) having the formula: Ac-D-Ala-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg- Gln-Arg-Tyr-NH 2 (SEQ TD NO: 220)
• the peptide NPY (19-36) having the formula: H-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-ne-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr- NH 2 (SEQ TD NO: 221)
• the peptide [Nle 17 ]-NPY (17-36) having the formula: H-Nle-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln- Arg-Tyr-NH 2 (SEQ ID NO: 222)
• the peptide [D-Ser 18 ]-NPY (18-36) having the formula: H-D-Ser-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg- Tyr-NH 2 (SEQ HD NO: 223)
• the peptide [Ala 17 , His 21 ]-NPY (17-36) having the formula: H-Ala-Ala-Arg-Tyr-His-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln- Arg-Tyr-NH 2 (SEQ ID NO: 224)
• the peptide [D-Ile 18 ]-NPY (18-36) having the formula: D-ne-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-He-Asn-Leu-Ile-Thr-Arg-Gln-Arg- Tyr-NH 2 (SEQ ID NO: 225)
• the peptide [Ac-Arg 17 ]-NPY (17-36) having the formula: Ac-Arg-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln- Arg-Tyr-NH 2 (SEQ TD NO: 226)
• the peptide [Phe 20 ]-NpY (18-36) having the formula: H-Ala-Arg-Phe-Tyr-Ser-Ala-Leu-Arg-His-Tyr-He-Asn-Leu-Ile-Thr-Arg-Gln-Arg- Tyr-NH 2 (SEQ ID NO: 228)
• the peptide [ 1 MeLeu 17 ]-pNPY (17-36) having the formula: H-N a MeLeu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg- Gln- Arg-Tyr-NH 2 (SEQ ID NO: 230)
• the peptide [desamino Ala 18 ]-NpY (18-36) having the formula: desamino-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg- Gln-Arg-Tyr- NH 2 (SEQ ID NO: 231)
• the peptide [Thr 22 , Gln 23 ]-NPY (18-36) having the formula: H-Ala-Arg-Tyr-Tyr-Thr-Gln-Leu-Arg-His-Tyr-He-Asn-Leu-Ile-Thr-Arg-Gln-Arg- Tyr-NH 2 (SEQ ID NO: 234)
• the peptide [Gin 2 Phe 36 ]-NPY (17-36) having the formula: H-Leu-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-Gln-Tyr-Arg-Asn-Leu-Ile-Thr-Arg-Gln- Arg-Phe-NH 2 (SEQ ID NO: 238)
• the peptide pPYY (18-36) having the formula: H-Ser-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg- Tyr-NH 2 (SEQ ID NO: 240)
• the peptide [D-Ala 17 , Val 28 , Phe 32 ]-NPY (17-36) having the formula: D-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Val-Asn-Leu-He-Phe-Arg-Gln-Arg- Tyr-NH 2 (SEQ TD NO: 246)
• H-C a MeSer-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Met-Ile-Thr-Arg-Gln-Arg- Phe-NH 2 (SEQ ID NO: 247)
• the peptide [Ser 18 , Phe 27 ]-pNPY (17-36) having the formula: H-Leu-Ser-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Phe-Ile-Asn-Leu-Ile-Thr-Arg-Gln- Arg-Tyr-NH 2 (SEQ ID NO: 249)
• the peptide [D-Ser 18 , Phe 36 ]-NPY (18-36) having the formula: H-D-Ser-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg- Phe-NH 2 (SEQ TD NO: 251)
• the peptide [Glu 23 , He 29 ]-NPY (18-36) having the formula: H-Ala-Arg-Tyr-Tyr-Ser-Glu-Leu-Arg-His-Tyr-Ile-ne-Leu-Ile-Thr-Arg-Gln-Arg- Tyr-NH 2 (SEQ TD NO: 253)
• the peptide [D-Ala 17 ]-NPY(17-36)-OH having the formula: D-Ala-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln- Arg-Tyr-OH (SEQ ID NO: 254).
• X is a chain of 0-5 amino acids, inclusive, the N-terminal one of which is bonded to Rt and R 2
• Y is a chain of 0-4 amino acids, inclusive, the C-terminal one of which is bonded to R 3 and R 4
• Ri is H, Ci -C2 alkyl (e.g., methyl), C 6 -C 18 aryl (e.g., phenyl, napthaleneacetyl), -Cu acyl (e.g., formyl, acetyl, and myristoyl), C -C 18 aralkyl (e.g., benzyl), or C -C 18 alkaryl (e.g., p-methylphenyl);
• Ci -C2 alkyl e.g., methyl
• C 6 -C 18 aryl e.g., phenyl, napthaleneacetyl
• -Cu acyl e.g., formyl, acetyl, and myristoyl
• C -C 18 aralkyl e.g., benzyl
• C -C 18 alkaryl e.g., p-methylphenyl
• R 2 is H, Ci -C 12 alkyl (e.g., methyl), C 6 -C 18 aryl (e.g., phenyl, naphthaleneacetyl), Ci -C 12 acyl (e.g., formyl, acetyl, and myristoyl), C -C 18 aralkyl (e.g., benzyl), or C 7 -C ⁇ 8 alkaryl (e.g., p-methylphenyl);
• Ci -C 12 alkyl e.g., methyl
• C 6 -C 18 aryl e.g., phenyl, naphthaleneacetyl
• Ci -C 12 acyl e.g., formyl, acetyl, and myristoyl
• C -C 18 aralkyl e.g., benzyl
• C 7 -C ⁇ 8 alkaryl e.g., p-methyl
• a 22 is an aromatic amino acid, Ala, Aib, Arib, N-Me-Ala, or is deleted;
• a 23 is Ser, Thr, Ala, N-Me-Ser, N-Me-Thr, N-Me-Ala, or is deleted;
• a 24 is Leu, lie, Vat, Trp, Gly, Aib, Anb, N-Me-Leu, or is deleted;
• a 25 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-e-NH-R (where R is H, a branched or straight chain Ci -C 10 alkyl group, or an aryl group), Orn, or is deleted;
• a 26 is His, Thr, 3-Me-His, 1-Me-His, /3-pyrozolylalanine, N-Me-His, Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-e-NH-R (where R is H, a branched or straight chain Ci -C 10 alkyl group, or an aryl group), Orn, or is deleted;
• a 27 is an aromatic amino acid other than Tyr;
• a 28 is Leu, He, Vat, Trp, Aib, Aib, Arib, or N-Me-Leu;
• a 29 is Asn, Ala, Gin, Gly, Trp, or N-Me-Asn;
• a 30 is Leu, He, Val, Trp, Aib, Anb, or N-Me-Leu;
• a 31 is Vat, He, Trp, Aib, Anb, or N-Me-Val;
• a 32 is Thr, Ser, N-Me-Set, or N-Me-Thr;
• R 3 is H, d -C 12 alkyl (e.g., methyl), C 6 -C 18 aryl (e.g., phenyl, naphthaleneacetyl), Ci -C 12 acyl (e.g., formyl, acetyl, and myristoyl), C 7 -C 18 aralkyl (e.g., benzyl), or C 7 -C 18 alkaryl (e.g., p-methylphenyl);
• R-t is H, d -C 12 alkyl (e.g., methyl), C 6 -C 18 aryl (e.g., phenyl, naphthaleneacetyl), Ci -C 12 acyl (e.g.,
• P articularly preferred agonists of this formula to be used in the method of the disclosure include:
• Y is a chain of 0-4 amino acids, inclusive the C-terminal one of which bonds to R3 andR4;
• Ri is H, d -C 12 alkyl, C 6 -C 18 aryl, Ci -C 12 acyl, C 7 -C 18 aralkyl, or C 7 -C 18 alkaryl;
• R 2 is H, Ci -C12 alkyl, C 6 -Cis aryl, Ci -C12 acyl, C 7 -C ⁇ 8 aralkyl, or C 7 -C ⁇ 8 alkaryl;
• a 25 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-e-NH-R (where R is H, a branched or straight chain Ci -C 10 alkyl group, or an aryl group), Orn, or is deleted;
• a 26 is Ala, His, Thr, 3-Me-His, 1-Me-His, j3-pyrozolylalanine, N-Me-His,
• Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-e-NH-R where R is H, a branched or straight chain Ci -Cio alkyl group, or an aryl group), Orn or is deleted;
• a 27 is an aromatic amino acid
• a 28 is Leu, He, Val, Trp, Aib, Anb, or N-Me-Leu
• a 29 is Asn, Ala, Gin, Gly, Trp, orN-Me-Asn
• a 30 is Leu, He, Val, Trp, Aib, Anb, or N-Me-Leu
• a 31 is Val, He, Trp, Aib, Anb, orN-Me-Val
• a 32 is Thr, Set, N-Me-Set, or N-Me-Thr or D-Trp;
• R 3 is H, C1-C12 alkyl, C 6 -Qs aryl, d -C12 acyl, C 7 -C ⁇ 8 aralkyl, or C 7 -C 18 alkaryl;
• each amino acid residue e.g., Leu and A 1
• R represents the structure of NH ⁇ C(R)H ⁇ CO ⁇ , in which R is the side chain. Lines between amino acid residues represent peptide bonds which join the amino acids. Also, where the amino acid residue is optically active, it is the L- form configuration that is intended unless D-form is expressly designated.
• X is a chain of 0-5 amino acids, inclusive, the N-terminal one of which is bonded to Ri and R 2 ;
• Y is a chain of 0-4 amino acids, inclusive, the C-terminal one of which is bonded to R 3 and R 4 ;
• Ri is H, Q-C 1 2 alkyl (e.g. methyl), C ⁇ -Cig aryl (e.g., phenyl, naphthaleneacetyl), C ⁇ -C 12 acyl (e.g., formyl, acetyl, and myristoyl), C -C ⁇ S aralkyl (e.g., benzyl), or C7-C 18 alkaryl (e.g., p-methylphenyl);
• C ⁇ -Cig aryl e.g., phenyl, naphthaleneacetyl
• C ⁇ -C 12 acyl e.g., formyl, acetyl, and myristoyl
• C -C ⁇ S aralkyl e.g., benzyl
• C7-C 18 alkaryl e.g., p-methylphenyl
• R2 is H, Q-C 1 2 alkyl (e.g., methyl), C 6 -Ci8 aryl (e.g., phenyl, naphthaleneacetyl), C 1 -Q 2 acyl (e.g., formyl, acetyl, and myristoyl), C 7 -C 18 ar_alkyl (e.g., benzyl), or C 7 -C ⁇ 8 alkaryl (e.g., p-methylphenyl);
• Q-C 1 2 alkyl e.g., methyl
• C 6 -Ci8 aryl e.g., phenyl, naphthaleneacetyl
• C 1 -Q 2 acyl e.g., formyl, acetyl, and myristoyl
• C 7 -C 18 ar_alkyl e.g., benzyl
• C 7 -C ⁇ 8 alkaryl e.g
• a 22 is an aromatic amino acid, Ala, Aib, Anb, N-Me-Ala, or is deleted;
• a 23 is Ser, Thr, Ala, Aib, N-Me-Ser, N-Me-Thr, N Me-Ala, or is deleted;
• a 24 is leu, He, Val, Trp, Gly, Nle, Nva, Aib, Anb, N-Me-Leu, or is deleted;
• a 25 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lye-e-NH-R (where R is H, a branched or straight chain C ⁇ -C 10 alkyl group, or an aryl group), Orn, or is deleted;
• a 26 is Ala, His, Thr, 3-Me-His, 1-Me-His, ⁇ -pyrozolylalanine, N-Me-His,
• Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R where R is H, a branched or straight chain Ci-C 10 alkyl groups or an aryl group), Orn, or is deleted;
• A is an aromatic amino acid other than Tyr
• a 28 is Leu, He, Val, Trp, Nle, Nva, Aib, Anb, or N-Me-Leu;
• a 29 is Asn, Ala, Gin, Gly, Trp, or N-Me-Asn;
• a 30 is Leu, He, Val, Trp, Nle, Nva, Aib, Anb, or N-Me-Leu;
• a 31 is Val, Leu, He, Trp, Nle, Nva, Aib, Anb, or N-Me-Val;
• a 32 is Thr, Ser, N-Me-Ser, N-Me-Thr, or D-Trp;
• R 3 is H, Ci-C 12 alkyl (e.g., methyl), C 6 -C 18 aryl (e.g., phenyl, naphthaleneacetyl), Ci-C 12 acyl (e.g., formyl, acetyl, and myristoyl), C 7 -C 18 aralkyl (e.g., benzyl), or C 7 -Ci 8 alkaryl (e.g., p-methylphenyl); and
• R4 is H, C ⁇ -Ci 2 alkyl (e.g., methyl), C 6 -Ci8 aryl (e.g., phenyl, naphthaleneacetyl), C 1 -Q 2 acyl (e.g., formyl, acetyl, and myristoyl), C 7 -C ⁇ 8 aralkyl (e.g., benzyl), or C -C ⁇ s alkaryl (e.g., p-methylphenyl), or a pharmaceutically acceptable salt thereof.
• C ⁇ -Ci 2 alkyl e.g., methyl
• C 6 -Ci8 aryl e.g., phenyl, naphthaleneacetyl
• C 1 -Q 2 acyl e.g., formyl, acetyl, and myristoyl
• C 7 -C ⁇ 8 aralkyl e.g., benzyl
• a 27 is Phe, Nal, Bip, Pep, Tic, Trp, Bth, Thi, or
• X is A 17 -A * 18 -A A 19 -A A 20 -A A 21 wherein A 17 is Cys, Leu, He, Val, Nle, Nva, Aib, Anb, or N-Me-Leu; A 18 is Cys, Ser, Thr, N-Me-Ser, or N-Me-Thr;
• a 19 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain Ci-C 10 alkyl group, or C ⁇ -Cis aryl group), Cys, or Orn;
• R is H, a branched or straight chain Ci-C 10 alkyl group, or C ⁇ -Cis aryl group), Cys, or Orn;
• a 20 is an aromatic amino acid, or Cys;
• A is an aromatic amino acid, Cys, or a pharmaceutically acceptable salt thereof.
• Y is A 33 -A 34 -A 35 -A 36 wherein
• a 33 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain C1-Q 0 alkyl group, or an aryl group), Cys, or Orn;
• a 34 is Cys, Gin, Asn, Ala, Gly, N-Me-Cln, Aib, or Anb;
• a 35 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain Ci-Cio alkyl group, or C 6 -Ci8 aryl group), Cys, or Orn; and
• a 36 is an aromatic amino acid, Cys or a pharmaceutically acceptable salt thereof. See U.S. Patent No. 5,604,203.
• Particular embodiments include compounds has the formula: N- ⁇ -Ac-Ala- Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gin-Arg-Tyr-NH 2 (SEQ. ID. NO: 325), H-Ala-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH 2 (SEQ. ID. NO: 326), N- ⁇ -Ac-Ala-Ser-Leu-Arg-Thr-Arg-Gin-Arg-Tyr-NH 2 (SEQ. ID.
• PYY agonists have the formula: II)
• N-terminal amino acid is bounded to Ri and R 2 ;
• Y is a chain of 0-4 amino acids, inclusive the C-terminal one of which is bonded to R 3 and R4;
• Ri is H, C ⁇ -C 12 alkyl (e.g., methyl), C 6 -Ci 8 aryl (e.g., phenyl, naphthaleneacetyl), Ci-C 12 acyl (e.g., formyl, acetyl, and myristoyl), C 7 -Ci8 aralkyl (e.g., benzyl), or C 7 -Ci8 alkaryl (e.g., p-methylphenyl);
• C ⁇ -C 12 alkyl e.g., methyl
• C 6 -Ci 8 aryl e.g., phenyl, naphthaleneacetyl
• Ci-C 12 acyl e.g., formyl, acetyl, and myristoyl
• C 7 -Ci8 aralkyl e.g., benzyl
• C 7 -Ci8 alkaryl e.g.,
• R is H, C1-C12 alkyl (e.g., methyl), C 6 -C ⁇ 8 aryl (e.g., phenyl, naphthaleneacetyl), Ci-Ci 2 acyl (e.g., formyl, acetyl, and myristoyl), C 7 -C 18 aralkyl (e.g., benzyl), or C 7 -Ci 8 alkaryl (e.g., p-methylphenyl);
• C1-C12 alkyl e.g., methyl
• C 6 -C ⁇ 8 aryl e.g., phenyl, naphthaleneacetyl
• Ci-Ci 2 acyl e.g., formyl, acetyl, and myristoyl
• C 7 -C 18 aralkyl e.g., benzyl
• C 7 -Ci 8 alkaryl e.g.,
• a 25 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain Q-Cio alkyl group, or an aryl group), Orn, or is deleted;
• a 26 is Ala, His, Thr, 3-Me-His, 1-Me-His, ⁇ -pyrozolylalanine, N-Me-His, Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain Ci-C 10 alkyl groups or an aryl group), Orn, or is deleted;
• A is an aromatic amino acid
• a 28 is Leu, He, Val, Tip, Nle, Nva, Aib, Anb, or N-Me-Leu;
• a 29 is Asn, Ala, Gin, Gly, Trp, or N-Me-Asn;
• a 30 is Leu, lie, Val, Trp, Nle, Nva, Aib, Anb, or N-Me-Leu;
• a 31 is Val, He, Trp, Nle, Nva, Aib, Anb, or N-Me-Val;
• a 32 is Thr, Ser, N-Me-Ser, N-Me-Thr, orD-Trp;
• R 3 is H, Ci -Ci 2 alkyl (e.g., methyl), C 6 -C ⁇ 8 aryl (e.g., phenyl, naphthaleneacetyl), Ci-C 12 acyl (e.g., formyl, acetyl, and myristoyl), C7-C 18 aralkyl (e.g., benzyl), or C 7 -C ⁇ 8 alkaryl (e.g., p-methylphenyl); and
• Rt is H, C 1 -C 12 alkyl (e.g., methyl), C6-C 18 aryl (e.g., phenyl, naphthaleneacetyl), Ci-Ci 2 acyl (e.g., formyl, acetyl, and myristoyl), C -C 18 aralkyl (e.g., benzyl), or C 7 -C 18 alkaryl (e.g., p-methylphenyl), or a pharmaceutically acceptable salt thereof. See U.S. Patent No. 5,604,203.
• a 27 is Phe, Nal, Bip, Pep, Tic, Trp, Bth, Thi, or Dip.
• X is A 33 -A 34 -A 35 -A 36 wherein A 33 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain Ci-C 10 alkyl group, or C 6 -C ⁇ 8 aryl group), Cys, or Orn;
• a 34 is Gin, Asn, Ala, Gly, N-Me-Gin, Aib, Cys, or Anb;
• a 35 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain C 1 -C 1 0 alkyl group, or C ⁇ -Cig aryl group), Cys, or Orn; and
• a 36 is an aromatic amino acid, Cys, or a pharmaceutically acceptable salt thereof.
• the compound has the formula: N- ⁇ -Ac-Arg-His-Phe-Leu-Asn- Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH 2 (SEQ. ID. NO: 324).
• Examplary PYY agonists include:
• PYY agonists include neurophilic Y Y2 receptor specific peptides having the formula:
• XI is NH, CH 3 CO or one or two naturally occurring amino acids.
• X2 is Leu, He or Val.
• X3 is Arg, Lys or His.
• X4 is His, Lys or Arg.
• X5 is Tyr or Phe.
• X6 is Leu, He or Val.
• X7 is Asn or Gin.
• X8 is Leu, He or Val.
• X9 is Leu, He or Val.
• X10 is Thr or Ser.
• XI I is Arg, His or Lys.
• X12 is Gin or Asn.
• XI 3 is Arg, His or Lys.
• X14 is Tyr or Phe.
• XI 5 is COOH, NH 2 or one or two naturally occurring amino acids with the terminal amino acid being in the normal or carboxamide form; and n is 1 to 5. See U.S. Patent No. 5,696,093.
• Examplary agonists include:
• PYY agonists have the formula:
• Particular compounds of the immediately foregoing group of compounds are where R 1 is acetyl and ⁇ is --CH 2 -NH-.
• a particular group of compounds is selected from a group consisting of
• N- ⁇ -Ac-rNle 24 ' 28,30 Tip 27 , Nva 31 , ⁇ 35/36 ]PYY(22-36)-NH 2 , (SEQ TD NO: 302) N- ⁇ -Ac-[Nle 24,28 , Tip 27 ' 30 , Nva 31 , ⁇ 35136 ]PYY(22-36)-NH 2 , (SEQ ID NO:
• Another particular compound has the formula N- ⁇ -Ac-[Nle 24,28 , Trp 30 , Nva.sup. 31 , ⁇ 35/36 ]PYY(22-36)-NH 2 (SEQ. HD. NO: 309) or a pharmaceutically acceptable salt thereof.
• Another PYY agonist has the formula (A),
• each pseudopeptide bond is independently selected from the group consisting of --CH2 ⁇ NH ⁇ , --CH 2 ⁇ S ⁇ , -
• R 10 is a chain of 0-5 amino acids, inclusive, where the N-terminal amino acid is bonded to R 1 and R 2 by the side chain of the N-terminal amino acid or by the nitrogen of the amino group of the N-terminal amino acid; ⁇
• R is a chain of 0-4 amino acids, inclusive, where the C-terminal amino acid is bonded to R 3 and R 4 by the side chain of the C-terminal amino acid or by the carbon of the carboxyl group of the C-terminal amino acid;
• R 1 , R 2 , R 3 and R 4 are each independently selected from the group consisting of H, (Ci -C 12 )alkyl, (C 6 -C 18 )aryl, (Ci -C 12 )acyl, phenyl(Cj -C 12 )alkyl and ((Ci - Ci 2 )alkyl)i. 5 -phenyl;
• a 22 is an aromatic amino acid, Ala, Aib, Anb, N-Me-Ala or is deleted;
• a 23 is Ser, Thr, Ala, N-Me-Ser, N-Me-Thr, N-Me-Ala or is deleted;
• a 24 is Leu, He, Nle, Val, Trp, Gly, Aib, Anb, N-Me-Leu or is deleted;
• a 25 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-p.epsilon.-NH-Z, Orn or is deleted;
• a 26 is His, Thr, 3-Me-His, 1-Me-His, (8-pyrazolylalanine, N-Me-His, Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-e-NH-Z, Orn or is deleted;
• a 28 is Leu, He, Nle, Val, Trp, Aib, Anb or N-Me-Leu;
• a 29 is Asn, Ala, Gin, Gly, Trp or N-Me-Asn;
• a 30 is Leu, He, Nle, Fla, Val, Tip, Aib, Anb or N-Me-Leu;
• a 31 is Val, Nva, He, Trp, Aib, Anb or N-Me-Val; and A 32 is Thr, Ser, N-Me-Ser or N-Me-Thr; where Z for each occurrence is independently selected from the group consisting of H, (Ci -Cio)alkyl and (C 6 -C 18 )aryl; or a pharmaceutically acceptable salt thereof. See U.S. Patent No. 6,046,167.
• R 10 is A 17 -A 18 -A 19 -A 20 -A 21 ; where A 17 is Cys, Leu, He, Val, Nle, Nva, Aib, Anb or N-Me-Leu;
• a 18 is Cys, Ser, Thr, N-Me-Ser or N-Me-Thr;
• a 19 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-e-NH-R.sup.5, Cys or Orn;
• 9 ⁇ A is an aromatic amino acid or Cys
• A is an aromatic amino acid or Cys
• R 20 is A 33 -A 34 -A 35 -A 36 ,
• a 33 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-e-NH-R 5 , Cys or Orn;
• a 34 is Cys, Gin, Asn, Ala, Gly, N-Me-Gln, Aib or Anb;
• a 35 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-e-NH-R 5 , Cys or Orn;
• a 36 is an aromatic amino acid or Cys; where R 5 for each occurrence is independently selected from the group consisting of Hi (Ci -C ⁇ 0 )alkyl and (C 6 aryl.
• R 5 for each occurrence is independently selected from the group consisting of Hi (Ci -C ⁇ 0 )alkyl and (C 6 aryl.
• a particular group of compounds of the foregoing group of compounds are the compounds of the formula N- ⁇ -Ac-[Fla 27 )]PYY(25-36)-NH 2 and N- ⁇ -Ac-[Fla 27 ]PYY(22-36)-NH 2 or a pharmaceutically acceptable salt thereof.
• Another group of PYY agonist has the formula:
• -HN-CH-CO- it replaces the two amino acids that the optional bond is attached to; q is 1-4; m is 1 to 4; R 30 is OH or -O-R 1 , provided that when A 1 to A 7 are deleted then R 30 is also NH-R 1 , where R 30 is attached to the carbon atom of the carboxyl of the C-terminal amino acid;
• R 1 and R 2 for each occunence are each independently selected from the group consisting of H, (Ci -C 12 )alkyl, (C 6 -C 18 )aryl, (Ci -Ci2)acyl, phenyl(d - Ci2)alkyl and ((d -Ci 2 )aU yl)i. 5 -phenyl where R 1 and R 2 are attached to the nitrogen of the amine of the N-terminal amino acid;
• a 1 is deleted or D- or L- of the following amino acids: Trp, Tyr, Fla, Bth, Nal, Tic, Tic-OH, Dip, Bip or optionally substituted Phe where the Phe is optionally substituted with one to five substituents selected from the group consisting of (d - C 4 )alkyl, halo, (Ci -C )alkoxy, amino and nitro;
• a 2 is deleted or D- or L- of the following amino acids: He, Val, Leu, Nle, Anb, Aib, Pro, Gin or Asn;
• a 3 is deleted or D- or L- of the following amino acids: Asn, Gin, Glu, Asp, Orn, Lys, Dpr or Cys;
• a 4 is deleted or D- or L- of the following amino acids: He, Val, Leu, Nle, Anb, Aib or Pro;
• a 5 is deleted or D- or L- of the following amino acids: He, Val, Leu, Nle, Anb, Aib, Pro, Glu, Asp, Orn, Lys, Dpr or Cys;
• a 6 is deleted or D- or L- of the following amino acids: Thr, Ser, Trp, Tyr,
• Fla Bth, Nal, Tic, Tic-OH, Dip, Bip or optionally substituted Phe where the Phe is optionally substituted with one to five substituents selected from the group consisting of (Ci -C )alkyl, halo, (d -C )alkoxy, amino and nitro;
• a 7 is deleted or D- or L- of the following amino acids: Arg, Lys, homo-Arg, dialkyl-homo-Arg, Lys-e-NH-R 7 or Orn;
• a 8 is deleted or D- or L- of the following amino acids: Nva, Val, He, Leu, Nle, Anb, Aib, Pro, Gin, Asn, Glu, Asp, Orn, Lys, Dpr or Cys;
• a 9 is deleted or D- or L- of the following amino acids: Arg, Lys, homo-Arg, dialkyl-homo-Arg, Lys-e-NH-R 7 or Orn; and A 10 is deleted or D- or L- of the following amino acids: Tyr, Trp, Fla, Bth,
• PYY and PYY agonists may be produced by recombinant DNA technology by chemical synthesis, from natural sources, or by any combination thereof.
• PYY and PYY agonists may be modified by well known processes such as amidation, glycosylation, acylation (e.g. acetylation), sulfation, phosphylation, cyclization, lipidization and pegylation.
• Methods for lipidization with fatty acid derivatives of sulfhydryl-containing compounds are disclosed in U.S. Patent No. 5,936,092; U.S. Patent No. 6,093,692; and U.S. Patent No. 6,225,445.
• Fatty acid derivatives of sulfhydryl-containing PYY and PYY agonists comprising fatty acid-conjugated products with a disulfide linkage are employed for delivery of the PYY and PYY agonists to neuronal cells and tissues.
• This modification markedly increases the absorption of the compounds relative to the rate of absorption of the unco ⁇ jugated compounds, as well as prolonging blood and tissue retention of the compounds.
• the disulfide linkage in the conjugate is quite labile in the cells and thus facilitates intracellular release of the intact compounds from the fatty acid moieties.
• Fatty acids as constituents of phospholipids, make up the bulk of cell membranes. Due to their lipidic nature, fatty acids can easily partition into and interact with the cell membrane in a non-toxic way. Therefore, fatty acids represent potentially a useful carrier ligand for the delivery of proteins and peptides.
• a sulfhydryl-containing PYY and PYY agonist is attached to a fatty acid derivative via a reversible, biodegradable disulfide bond.
• a conjugate is expected to bind to the apical side of a cell membrane, reach the basolateral membrane of the Gl-epithelium as a result of membrane transport and turnover, and become released into interstitial fluid as the result of disulfide bond reduction.
• Such lipidized PYY and PYY agonist compounds have the general formula
• P is a residue derived from a PYY or PYY agonist
• R 1 is hydrogen, lower alkyl or aryl
• R 2 is a lipid-containing moiety
• R 3 is --OH, a Upid-containing moiety or an amino acid chain comprising one or 2 amino acids and terminating in - CO 2 H or -COR 2 .
• P is a residue derived from a PYY or PYY agonist
• R 1 is hydrogen, lower alkyl or aryl
• R 2 is a lipid-containing moiety
• R 3 is --OH, a Upid-containing moiety or an amino acid chain comprising one or 2 amino acids and terminating in - CO 2 H or -COR 2 .
• Typical alkyl groups include C ⁇ - 6 alkyl groups including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 2-methyl-l -pentyl, 3-methyl-l -pentyl, 4-methyl- 1 -pentyl, and the like.
• Preferred aryl groups are Ce- ⁇ 4 aryl groups and typically include phenyl, naphthyl, fluorenyl, phenanthryl, and anthracyl groups.
• lipid-containing moiety refers to either a lipid group per se or a hydrocarbon-based group (in particular, one or more amino acids) comprising a lipid group.
• lipid group is meant a hydrophobic substituent consisting of 4 to 26 carbon atoms, preferably 5 to 19 carbon atoms. Suitable lipid groups include, but are not limited to, the following: palmityl (C15H31,), oleyl (C15H 2 9), stearyl (Ci7H 35 ), cholate; and deoxycholate.
• R 2 is selected from the group consisting of hydrogen, halo, alkyl, or aryl, wherein the alkyl or aryl groups are optionally substituted with one or more alkoxy, alkoxyalkyl, alkanoyl, nitro, cycloalkyl, alkenyl, alkynyl, alkanoyloxy, alkyl or halogen atoms;
• R 3 is a lipophilic group; one of R 4 and R 5 is a PYY or a PYY agonist and the other of R 4 and R 5 is OR 6 where R 6 is hydrogen, an alkali metal or a negative charge; X is oxygen or sulfur;
• Y is a bridging natural or unnatural amino acid; n is zero or 1 ; and m is an integer
• Typical alkyl groups include C ⁇ - 6 alkyl groups including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 2-methyl-l-pentyl, 3-methyl-l-pentyl, 4-methyl- 1 -pentyl, and the like.
• Typical alkoxy groups include oxygen substituted by any of the alkyl groups mentioned above.
• Typical alkoxyalkyl groups include any of the above alkyl groups substituted by an alkoxy group, such as methoxymethyl, ethoxymethyl, propoxymethyl, butoxymethyl, pentoxymethyl, hexoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, methoxypentyl, methoxyhexyl, and the like.
• Preferred aryl groups are C 6 -i 4 aryl groups and typically include phenyl, naphthyl, fluorenyl, phenanthryl, and anthracyl groups.
• Typical alkoxy substituted aryl groups include the above aryl groups substituted by one or more of the above alkoxy groups, e.g., 3-methoxyphenyl, 2- ethoxyphenyl, and the like.
• Typical alkyl substituted aryl groups include any of the above aryl groups substituted by any of the d- ⁇ alkyl groups, including the group Ph(CH 2 )n, where n is 1-6, for example, tolyl, o-, m-, and p-xylyl, ethylphenyl, 1-propylphenyl, 2- propylphenyl, 1-butylphenyl, 2-butylphenyl, t-butylphenyl, 1-pentylphenyl, 2- pentylphenyl, 3-pentylphenyl.
• Typical alkenyl groups include C 2 . 6 alkenyl groups, e.g. ethenyl, 2-propenyl, isopropenyl, 2-butenyl, 3-butenyl, 4-pentenyl, 3-pentenyl, 2-pentenyl, 5-hexenyl, 4- hexenyl, 3-hexenyl, and 2-hexenyl groups.
• Typical alkynyl groups include C 2 . 6 aU ynyl groups e.g. enthynyl, 2- propenyl, 2-butynyl, 3-butynyl, 4-pentynyl, 3-pentynyl, 2-pentynyl, 5-hexynyl, 4hexynyl, 3-hexynyl, and 2-hexynyl groups.
• Typical alkenyl or alkynyl substituted aryl groups include any of the above
• C ⁇ -1 4 aryl groups substituted by any of the above C 2 -6 alkenyl or d- ⁇ alkynyl groups e.g., ethenylphenyl, 1-propenylphenyl, 2-propenylphenyl, lbutenylphenyl, 2- butenylphenyl, 1-pentenylphenyl, 2-pentenylphenyl, 3-pentenylphenyl, 1- hexenylphenyl, 2-hexenylphenyl, 3-hexenylphenyl, ethynylphenyl, 1- propynylphenyl, 2-propynylphenyl, 1-butynylphenyl, 2-butynylphenyl, 1- pentynylphenyl, 2-pentynylphenyl, 3-pentynylphenyl, 1-hexynylphenyl, 2- hexynylphenyl, 3-he
• Typical halo groups include fluorine, chlorine, bromine, and iodine.
• Typical halo substituted alkyl groups include C ⁇ - 6 alkyl groups substituted by one or more fluorine, chlorine, bromine, or iodine atoms, e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, and trichloromethyl groups.
• Typical cycloalkyl groups include C 3 . 8 cycloalkyl groups including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups.
• lipophilic group refers to either a naturally occurring lipid per se, a hydrophobic branched or unbranched hydrocarbon comprising about 4 to about 26 carbon atoms, preferably about 5 to about 19 carbon atoms, a fatty acid or ester thereof, or a surfactant.
• Suitable lipophilic groups include, but are not limited to, long chain alkanoyl groups including: palmityl (C 15 H 31 ), oleyl (Ci5H 29 ), stearyl (d 7 H 35 ), lauryl (C ⁇ H 23 ), cholyl, andmyristyl (C 13 H 27 )
• natural or unnatural amino acid refers to any of the 21 naturally occurring amino acids as well as D-form amino acids, blocked L-and D- form amino acids such as those blocked by amidation or acylation, substituted amino acids (e.g., those substituted with a sterically hindered alkyl group or a cycloalkyl group such as cyclopropyl or cyclobutyl) in which the substitution introduces a conformational restraint in the amino acid.
• amino acids or components of a peptide or protein are alanine, arginine, asparagine, aspartic acid, citrulline, cysteine, cystine, y-glutamic acid, glutamine, glycine, histidine, isoleucine, norleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, hydroxyproline, serine, threonine, tryptophan, tyrosine, valine, ⁇ -carboxyglutamate, or O-phosphoserine.
• the preferred non-naturally occurring amino acids for use in the present disclosure as amino acids or components of peptides or proteins are any of the 3-amino acids, e.g., ⁇ -alanine, 7-amino butyric acid, 7-amino butyric acid, 7-(aminophenyl)butyric acid, ⁇ -amino isobutyric acid, e-amino caproic acid, 7-amino heptanoic acid, amino benzoic acid, aminophenyl acetic acid, aminophenyl butyric acid, cysteine (ACM), methionine sulfone, phenylglycine, norvaline, ornithine, ⁇ -ornithine, pnitro- phenylalanine, l,2,3,4-terahydroisoquinoline-3-carboxylic acid and thioproline.
• 3-amino acids e.g., ⁇ -alanine, 7-amin
• the present disclosure is also directed to methods of preparing lipidized conjugates of PYY and PYY agonists, pharmaceutical compositions comprising lipidized conjugates of PYY and PYY agonists, and methods of increasing the delivery of amino group-containing PYY and PYY agonists into a cell.
• modified derivatives of PYY and PYY agonists which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent No. 4,179,337).
• modified derivatives include PYY and PYY agonists modified by pegylation.
• pegylated and pegylation refer to the process of reacting a poly(alkylene glycol), preferably an activated poly(alkylene glycol), with a facilitator such as an amino acid, e.g. lysine, to form a covalent bond.
• pegylation is often carried out using ⁇ oly(ethylene glycol) or derivatives thereof, such as methoxy polyethylene glycol), the term is not intended to be so limited here, but is intended to include any other useful poly(alkylene glycol), such as, for example poly(propylene glycol).
• the chemical moieties for derivitization may also be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like.
• the polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.
• the polymer may be of any molecular weight, and may be branched or unbranched.
• the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about” indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing.
• Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).
• the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.
• polyethylene glycol may have a branched structure.
• Branched polyethylene glycols are described, for example, in U.S. Patent No.
• polyethylene glycol molecules should be attached to the polypeptides or proteins with consideration of effects on functional or antigenic domains of the polypeptides or proteins.
• attachment methods available to those skilled in the art, e.g., EP 0401 384 (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol 20:1028-1035, 1992 (reporting pegylation of GM-CSF using tresyl chloride).
• polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound.
• the amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; ⁇ those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue.
• Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.
• polyethylene glycol may be attached to proteins and polypeptides via linkage to any of a number of amino acid residues.
• polyethylene glycol can be linked to proteins and polypeptides via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues.
• One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the polypeptide or protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein or polypeptide.
• polyethylene glycol as an illustration, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (or peptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein.
• the method of obtaining the N-terminally pegylated preparation i.e., separating this moiety from other monopegylated moieties if necessary
• Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.
• pegylation of the proteins and polypeptides may be accomplished by any number of means.
• polyethylene glycol may be attached to the protein or polypeptide either directly or by an intervening linker.
• Linkerless systems for attaching polyethylene glycol to proteins and polypeptides are described in Delgado et al., Crit. Rev. Thera. Drug Carrier Sys. 9:249-304, 1992; Francis et al., Intern. J. ofHematol 68:1-18, 1998; U.S. Patent No. 4,002,531; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466.
• One system for attaching polyethylene glycol directly to amino acid residues of proteins and polypeptides without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride (ClSO 2 CH 2 CF 3 ).
• MPEG monmethoxy polyethylene glycol
• ClSO 2 CH 2 CF 3 tresylchloride
• polyethylene glycol is directly attached to amine groups of the protein or polypeptide.
• the disclosure includes protein- polyethylene glycol conjugates produced by reacting proteins and polypeptides with a polyethylene glycol molecule having a 2,2,2-trifluoreothane sulphonyl group.
• Polyethylene glycol can also be attached to proteins and polypeptides using a number of different intervening linkers.
• U.S. Patent No. 5,612,460 discloses urethane linkers for connecting polyethylene glycol to proteins.
• Protein- polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein or polypeptide by a linker can also be produced by reaction of proteins or polypeptides with compounds such as MPEG-succinimidylsuccinate, MPEG activated with l, -carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG- p -nitrophenolcarbonate, and various MPEG-succinate derivatives.
• MPEG-succinimidylsuccinate MPEG activated with l, -carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG- p -nitrophenolcarbonate, and various MPEG-succinate derivatives.
• the number of polyethylene glycol moieties attached to each protein or polypeptide may also vary.
• the pegylated proteins and polypeptides may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, or more polyethylene glycol molecules.
• the average degree of substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein or polypeptide molecule. Methods for determining the degree of substitution are discussed, for example, in Delgado et al., Crit. Rev. Thera. Drug Carrier Sys. 9:249-304, 1992.
• proteins and polypeptides containing substantially non-antigenic polymers may be prepared, for example, as described in U.S. Patent No. 5,428,128; U.S. Patent No. 6,127,355; and U.S. Patent No. 5,880,131.
• PEG poly(ethylene glycol)
• activation the hydroxyl end groups of the PEG must first be converted into reactive functional groups. This process is frequently referred to as “activation” and the product is called “activated PEG.”
• Methoxy poly(ethylene glycol) (mPEG) distally capped with a reactive functional group is often used.
• mPEG Methoxy poly(ethylene glycol)
• SS-PEG succinimidyl succinate derivative of PEG
• substantially non-antigenic polymers that may be employed in the practice of the present disclosure include materials such as dextran, polyvinyl pyrrolidones, polysaccharides, starches, polyvinyl alcohols, polyacrylamides, or other similar non-immunogenic polymers.
• materials such as dextran, polyvinyl pyrrolidones, polysaccharides, starches, polyvinyl alcohols, polyacrylamides, or other similar non-immunogenic polymers.
• the polymer is introduced into the peptide or protein molecule after being functionalized or activated for reaction and attachment to one or more amino acids.
• activation it is understood by those of ordinary skill in the art that the polymer is functionalized to include a desired reactive group. See, for example, U.S. Patent No. 4,179,337 and U.S. Patent No. 5,122,614.
• the hydroxyl end groups of poly(alkylene glycols) are converted and activated into reactive functional groups.
• the polymer is conjugated to a facilitator moiety prior to being introduced into the polypeptide or protein molecule.
• the facilitator moiety is preferably an amino acid such as lysine, however, non-amino acid moieties are also contemplated.
• multifunctionalized organic moieties such as alkyls or substituted alkyls. Such moieties can be prepared to have a nucleophilic functional group such as an amine and an electrophiUc group such as an acid as well as a suitably functionalized region for conjugating with the desired polymer or polymers.
• the facilitator moieties allow easier inclusion of a polymer into the peptide or protein molecule during synthesis.
• poly(alkylene glycols) coupled to facilitator amino acids or amino acid residues in polypeptides or proteins by means of suitable coupling agents are illustrative.
• a useful review of a number of coupling agents known in the art appears in Dreborg et al., Critical Reviews in Therapeutic Drug Carrier Systems 6(4):315-165, 1990, see especially, pp. 317-320.
• Pegylated PYY peptides and agonists can also be of the general formula
• D is a residue of a PYY peptide or agonist;
• X is an electron withdrawing group;
• Y and Y' are independently O or S;
• (n) is zero (0) or a positive integer, preferably from 1 to about 12;
• Ri and R 2 are independently selected from the group consisting of H, C ⁇ - 6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls, and substituted C ⁇ _ 6 alkyls;
• R 3 is a substantially non-antigenic polymer, d. ⁇ 2 straight or branched alkyl or substituted alkyl, Cs- 8 cycloalkyl or substituted cycloalkyl, carboxyalkyl, carboalkoxy alkyl, dialkylaminoalkyl, phenylalkyl, phenylaryl or
• R 4 and R5 are independently selected from the group consisting of H, d- 6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls and substituted C ⁇ - 6 alkyls or jointly form a cyclic C5-C 7 ring. See U.S. Patent No. 6,127,355.
• Typical alkyl groups include Ci-g alkyl groups including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 2-methyl-l-pentyl, 3 -methyl- 1 -pentyl, 4-methyl- 1-pentyl, and the like.
• Preferred aryl groups are C 6 . 1 aryl groups and typically include phenyl, naphthyl, fluorenyl, phenanthryl, and anthracyl groups.
• Typical alkyl substituted aryl groups include any of the above aryl groups substituted by any of the d- 6 alkyl groups, including the group Ph(CH 2 ) n , where n is 1-6, for example, tolyl, o-, m-, and p-xylyl, ethylphenyl, 1-propylphenyl, 2- propylphenyl, 1-butylphenyl, 2-butylphenyl, t-butylphenyl, 1-pentylphenyl, 2- pentylphenyl, 3-pentylphenyl.
• Typical cycloalkyl groups include C 3 . 8 cycloalkyl groups including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups.
• Typical electron withdrawing groups include O, NR 1? S, SO and SO 2 , wherein Ri is defined above.
• GLP-1 is produced from preproglucogon, which is a 160 amino acid polypeptide, in the central nervous system (CNS) and the intestine. It is released into the circulation in response to nutrient intake. Physiological actions of GLP-1 in man include stimulation of insulin release, suppression of gastric acid secretion and slowing of gastric emptying.
• GLP-1 (1-37) (SEQ ID NO: 336) is the initial product of the processing of preproglucagon. GLP-1 (1-37) is amidated by post-translational processing to yield GLP-1 (1-36) NH (SEQ ID NO 337), or is enzymatically processed to give GLP-1 (7-37) (SEQ ID NO: 338). GLP-1 (7-37) can be amidated to give GLP-1 (7-36) amide (SEQ ID NO: 339).
• the sequences of human GLP-1 are given below:
• GLP-1 (1-37) His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe The Ser Asp Val Ser Ser Tyr Leu Glu Gly Gly Ala Ala Lys Glu Phe He Ala Tip Leu Val Lys Gly Arg Gly (SEQ HD NO: 336).
• GLP-1 (1-36) amide His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe The Ser Asp Val Ser Ser Tyr Leu Glu Gly Gly Ala Ala Lys Glu Phe He Ala Trp Leu Val Lys GlyArg H 2 (SEQ TD NO: 337),
• GLP-1 (7-37): His Ala Glu Gly Thr Phe The Ser Asp Val Ser Ser Tyr Leu Glu Gly Gly Ala Ala Lys Glu Phe He Ala Trp Leu Val Lys Gly Arg Gly (SEQ ID NO: 338).
• GLP-1 (7-36) amide His Ala Glu Gly Thr Phe The Ser Asp Val Ser Ser Tyr Leu Glu Gly Gly Ala Ala Lys Glu Phe He Ala Trp Leu Val Lys Gly Arg NH 2 (SEQ ID NO: 339).
• a GLP-1 agonist is a peptide, small molecule, or chemical compound that preferentially binds to the GLP-1 receptor and stimulates the same biological activity as does GLP-1.
• an agonist for the GLP-1 receptor binds to the receptor with an equal or greater affinity than GLP-1.
• an agonist selectively binds the GLP-1 receptor, as compared to binding to another receptor.
• Exendin-4 which is a 39-amino acid peptide isolated from the salivary glands of the Gila monster (Heloderma suspectum) (Eng J et al J Biol Chem 267:7402-7405, 1992) is an example of an agonist at the GLP-1 receptor.
• GLP-1 agonists include GLP-1 related peptides and peptides that result from natural or synthetic enzymatic or chemical processing of preproglucagon or of a GLP-1 peptide or a related peptide.
• Any compound that is described as being a GLP-1 agonist may be used in the present invention, as may any compound that is tested for GLP-1 agonist activity, for example, as described above, and found to function as a GLP-1 agonist.
• a recombinant GLP-1 receptor suitable for use in screening is disclosed in WO93/19175. Many GLP-1 agonists are known and are described in the art.
• GLP-1 agonists examples include Arg34, Lys26(N-epsilon- (gamma-Glu(N-alpha-hexadecanoyl)))-GLP-l (7-37), IP7-GLP-1 (7-37)OH.
• GLP-1 or an agonist thereof may be administered according to the present invention peripherally at a dose of, for example, 0.1 nmoles or more per kg body weight of the subject, for example, 0.2 nmoles or more, for example, 0.4 nmoles or more, for example, 0.6 nmoles or more, for example, 0.8 nmoles or more, for example, 1.0 nmole or more, for example, 1.2 nmoles or more, for example, 1.4 nmoles or more, for example, 1.6 nmoles or more, for example, 1.8 nmoles or more, for example, 2.0 nmoles or more, for example, 2.2 nmoles or more, for example, 2.4 nmoles or more, for example, 2.6 nmoles or more, for example, 2.8 nmoles , for example, 3.0 nmoles or more, for example, up to 3.2 nmoles per kg body weight.
• the amount used may be up to 3.0 nmoles per kg body weight, for example, up to 2.8 nmoles, for example, up to 2.6 nmoles, for example, up to 2.4 nmoles, for example, up to 2.2 nmoles, for example, up to 2.0 nmoles, for example, up to 1.8 nmoles, for example, up to 1.4 nmoles, for example, up to 1.2 nmoles, for example, up to 1.0 nmoles, for example, up to 0.8 nmoles, for example, up to 0.6 nmoles, for example, up to 0.4 nmoles, for example, up to 0.2 nmoles per kg body weight.
• the dose is generally in the range of from 0.1 to 3.2 nmoles per kg body weight, for example, within any combination of upper and lower ranges given above.
• ICV intracerebro ventricular
• GLP-1 receptor antagonist exendin 9-39.
• GLP-1 receptors are found in the brainstem, arcuate nucleus and PVN.
• c-fos is expressed in the arcuate nucleus and PVN.
• peripheral administration of GLP-1 in man and rat also inhibits food intake and results in c-fos expression in the brainstem of rats.
• the effect on 1-hour food intake in non-fasted rats of IP administration of GLP-1 is not influenced by the presence of concomitant exendin 9-39, a GLP-1 receptor agonist, in the arcuate nucleus of the rat. This indicates that circulating GLP-1 acts via the brainstem rather than the arcuate nucleus.
• PYY when administered to humans, PYY was found to reduce appetite. When infused into humans at physiological post-prandial levels, PYY 3 . 36 significantly decreased appetite and reduced food intake by a third over 12 hours, and even by a third over 24 hours. Both the effect itself and the duration of the effect are surprising and unpredictable, as they occurred for many hours after the hormone had been cleared from the circulation. The effects, which are produced at physiological levels of the peptide, are strong indications that PYY acts in vivo to regulate feeding behavior.
• peripheral administration of PYY 3 . 36 in the rat caused an increase of c-fos immunoreactivity in the arcuate nucleus of the hypothalamus and a decrease in hypothalamic neuropeptide Y (NPY) mRNA.
• NPY hypothalamic neuropeptide Y
• electrophysiological studies demonstrated that PYY 3 . 36 inhibits synaptic activity of the NPY nerve terminals and thus activates POMC neurons, which are known to receive inhibitory NPY synaptic inputs.
• the natural pathway involves release of PYY from the gut, its conversion to PYY 3 . 36 , which acts as an agonist on the neuropeptide Y Y2 receptor (NPY Y2 receptor) in the brain.
• the NPY Y2 receptor acts as a inhibitory pre-synaptic receptor reducing release of neuropeptide Y, which is a most potent stimulator of feeding, and also acting on the anorexigenic melanocortin systems, the result of the NPY Y2 receptor activity being to suppress appetite and decrease food intake.
• the action of PYY 3 The action of PYY 3 .
• PYY 3 . 36 may occur in the arcuate nucleus of the hypothalamus, but other areas may be also be involved.
• the results obtained show that PYY 3 . 36 , a gut hormone that circulates in the blood, inhibits appetite at physiological concentrations, and that the inhibitory effect is observed even for some hours after the hormone has been cleared from the blood. This effect has been observed in all species tested, i.e. in mouse, rat and human.
• the circulating gut hormone appears to act via hypothalamic circuits.
• the reduction of messenger RNA, necessary for the synthesis of brain appetite regulating hormones, in particular of hypothalamic NPY mRNA may be a possible mechanism for the long action of PYY 3 . 6 .
• PYY 3 . 36 When PYY 3 . 36 was co-administered parenterally, either IP or IV with GLP-1, a clear synergistic reduction in food intake was produced. This contrasts with the results obtained with oxyntomodulin, where there was no synergistic effect, only a sum of the individual effects. As indicated above, PYY 3 . 36 is considered to act via the arcuate nucleus. Oxynotmodulin is also considered to act via that region of the brain. GLP-1, however, is believed to act via the brainstem, as explained above. While not being limited to the following, it appears that, when agents that act via different areas of the brain and/or by different neurological routes are administered parenterally, they produce a synergistic affect, whereas when they act by the same area and/or route they do not.
• the EGFP cassette was introduced by standard techniques into the 5' untranslated region of exon 2 of a mouse Pome genomic clone containing 13 kb of 5' and 2 kb of 3' flanking sequences (Young et al., JNeurosci 18, 6631-40, 1998).
• the transgene was microinjected into pronuclei of one-cell stage embryos of C57BL/6J mice (Jackson Laboratories) as described (Young et al., JNeurosci 18, 6631-40, 1998).
• mice One founder was generated and bred to wildtype C57BL/6J to produce Ni hemizygous mice. In addition, N 2 and subsequent generations of mice homozygous for the transgene were also generated. The mice are fertile and have normal growth and development.
• Immunq ⁇ uorescence and GFP co-localization Anesthetized mice were perfused transcardially with 4% paraformaldehyde and free-floating brain sections prepared with a vibratome. Sections were processed for immunofluorescence and colocalization of GFP fluorescence using standard techniques.
• Electrophysiology 200 ⁇ m thick coronal slices were cut from the ARC of four- week old male POMC-EGFP mice. Slices were maintained in (in mM) [NaCI, 126; KC1, 2.5; MgCl 2 , 1.2; CaCl 2 .2H 2 0, 2.4; NaH 2 PO4.H 2 0, 1.2; NaHCO 3 , 21.4; Glucose, 11.1] (Krebs) at 35°C and saturated with 95% O 2 5% CO 2 for 1 hour(hr) prior to recordings. Recordings were made in Krebs at 35° C.
• I-V relationships for the Met-Enk currents were established using a step protocol; (- 60 mV holding potential, sequentially pulsed (40 ms) from -120 to -50 mV, cells were returned to -60 mV for 2 s between voltage steps). The protocol was repeated after Met Enk addition. The net current was the difference between the two I-V relationships. This protocol was repeated in Krebs with 6.5 mM K + . I-V relationships to identify the postsynaptic leptin current were performed similarly with slow voltage ramps (5 mV/ s from -100 to -20 mV) before and 10 minutes after the addition of leptin (100 nM). GAB Aergic IPSCs were recorded using a
• IPSCs and excitatory postsynaptic currents were distinguished on the basis of their decay constants; additionally picrotoxin (100 ⁇ M) blocked all IPSCs. POMC neurons receive a low EPSC tone and the frequency was not modulated by any of the treatments described here.
• mice Male Pomc-EGFP mice were studied at 5-6 weeks of age and were generated as described above. K2r-null mice were generated using Cre-lox P mediated recombination, which results in the germline deletion of the entire coding region of the Y2 receptor. All F2r-null mice were maintained on a mixed C57/B16- 129SvJ background. Male mice aged 8-12 weeks and between 20-30 g bodyweight were kept under controlled temperature (21-23° C) and light conditions (lights on 06:00-18:00) with ad libitum access to water and food (Gordon's Speciality Stock feeds) except where stated. All studies were performed in the early light-phase (0700-0800).
• Intraperitoneal injections Rats were accustomed to IP injection by injections of 0.5 ml saline on the two days prior to study. For all studies, animals received an IP injection of PYY 3 . 36) GLP-1 or saline in 500 ⁇ l (for rats) or 100 ⁇ l (for mice).
• Electrophysiology Whole cell patch clamp recordings were made from POMC neurons in the hypothalamus of 180 ⁇ m thick coronal slices from Pomc- EGFP mice, as previously reported (Cowley et al., Nature 411, 480-484, 2001). "Loose cell-attached" recordings were made using extracellular buffer in the electrode solution, and maintaining seal resistance between 3-5Mohm throughout the recording.
• Firing rates were analysed using mini-analysis protocols (Mim ' Analysis, Jaejin Software, NJ). Vehicle controls were used in this system, previously validated for the electrophysiological actions of neuropeptides (Cowley et al., Nature 411, 480-484, 2001). Data were analysed by ANOVA, Neuman-Keuls posthoc comparison, and Wilcoxon Signed Rank Test.
• hypothalamic explants Male Wistar rats were killed by decapitation and the whole brain immediately removed, mounted with the ventral surface uppermost and placed in a vibrating microtome (Biorad, Microfield Scientific Ltd., Devon, UK). A 1.7 mm slice was taken from the base of the brain to include the PVN and the ARC and immediately transferred to 1ml of artificial CSF (aCSF) (Kim et al., J. Clin. Invest. 105, 1005-11, 2000) equilibrated with 95% O 2 and 5% CO 2 and maintained at 37° C.
• aCSF artificial CSF
• the hypothalami were then incubated for 45 minutes in 600 ⁇ l aCSF (basal period) before being exposed to the Y2A (50nM) in 600 ⁇ l aCSF. Finally, the viability of the tissue was verified by a 45 minute exposure to 56 mM KCL; isotonicity was maintained by substituting K + for Na + . At the end of each period, the aCSF was removed and frozen at -20° C until assayed for NPY and ⁇ MSH by radioimmunoassay.
• C-fos expression was measured in adult Wistar rats and
• Plasma assays Human leptin was measured using a commercially available radioimmunoassay (RIA) (Linco Research, USA). All other plasma hormone levels were measured using established in-house RIAs (Tarling et al., Intensive Care Med. 23, 256-260, 1997). Glucose concentrations were measured using a YSI 2300STAT analyser (Yellow Springs Instruments Inc., Ohio, USA). Plasma paracetamol levels were measured using an enzymatic colorimetric assay (Olympus AU600 analyzer).
• RIA radioimmunoassay
• PYY 3 . 36 was purchased from Bachem (California, USA). The Limulus Amoebocyte Lysate assay test for pyrogen was negative and the peptide was sterile on culture. Ethical approval was obtained from the Local Research Ethics Committee (project registration 2001/6094) and the study was performed in accordance with the principles of the Declaration of Helsinki. Subjects gave informed written consent. Each subject was studied on two occasions with at least 1 week between each study. Volunteers filled out a food diary for three days prior to each infusion, and for the following 24 hours. All subjects fasted and drank only water from 20:00 on the evening prior to each study.
• OXYMAX OXYMAX
• the equipment measures O 2 consumption and CO 2 production; the efficiency with which the body produces CO 2 from O 2 gives a reliable index of caloric or metabolic efficiency.
• a similar system is used with human volunteers.
• a strain of transgenic mice was generated expressing green fluorescent protein (EGFP Clontech), under the transcriptional control of mouse Pome genomic sequences that include a region located between -13 kb and -2 kb required for accurate neuronal expression (Young et al., JNeurosci 18, 6631-40, 1998) (Fig. la).
• Bright green fluorescence (509 nm) was seen in the two CNS regions where POMC is produced: the ARC and the nucleus of the solitary tract.
• Under ultraviolet (450- 480 nm) excitation POMC neurons were clearly distinguished from adjacent, non- fluorescent neurons (Fig. lb) visualized under infrared optics.
• POMC-EGFP neurons in hypothalamic slices had a resting membrane potential of -40 to -45 mV and exhibited frequent spontaneous action potentials.
• Met-Enk 30 ⁇ M; Sigma
• GIRK G protein coupled, inwardly-rectifying potassium channels
• POMC cells identified by post-recording immunohistochemistry, suggests that expression of the EGFP transgene does not compromise either expression of receptors nor their coupling to second messenger systems in POMC neurons.
• leptin The electrophysiological effects of leptin reported here are consistent with leptin' s biological actions; leptin rapidly causes release of ⁇ - MSH from rat hypothalami (Kim et al., J Clin Invest 105, 1005-11, 2000), presumably by activating POMC neurons.
• NPY Y2 receptors Both the leptin and NPY Y2 receptors are expressed on NPY neurons in the ARC (Hakansson et al., JNeurosci 18, 559-72, 1998; Broberger et al., Neuroendocrinology 66, 393-408, 1997). Furthermore, activation of Y2 receptors inhibits NPY release from NPY neurons (King et al., J Neurochem 73, 641-6, 1999), and presumably would also diminish GABA release from NPY/GABA terminals. This is an alternative pharmacological approach, independent of leptin, to test the hypothesized innervation of POMC neurons by GABAergic NPY neurons.
• NPY 100 nM; Bachem
• NPY and leptin still inhibited IPSCs in the presence of tetrodotoxin (TTX) (6 of 6 and 3 of 5 cells respectively), indicating that some of the inhibition of IPSCs was occurring through direct effects at presynaptic nerve terminals.
• a detailed model of regulation of this circuit shows dual mechanisms of leptin action in the ARC, interactions between NPY/GABA and POMC neurons, and autoregulatory feedback from opioid and melanocortin peptides as well as NPY (Fig. 4f).
• leptin directly depolarizes the POMC neurons and simultaneously hyperpolarizes the somata of NPY/GABA neurons, and diminishes release from NPY/GABA terminals. This diminished GABA release disinhibits the POMC neurons, and result in an activation of POMC neurons and an increased frequency of action potentials.
• PYY 3 . 36 is a gut-derived hormone that is released postprandially in proportion to the calories ingested (Pedersen-Bjergaard et al., Scand. J. Clin. Lab. Invest. 56, 497-503, 1996). The effects of peripheral administration of PYY 3 . 36 on feeding were investigated.
• IP PYY 3 . 36 caused a 2.6 fold increase in the proportion of POMC neurons that express c-fos (PYY 3 .
• PYY 3 . 36 shows a 70% amino acid sequence identity to NPY and acts through NPY receptors (Soderberg et al., J. Neurochem. 75, 908-18, 2000).
• the Y2R is a putative inhibitory presynaptic receptor and is highly expressed on the arcuate NPY neurons (Broberger et al, Neuroendocrinology 66, 393-408, 1997), though not on the neighboring POMC neurons.
• PYY 3 . 36 is a high affinity agonist at the Y2 receptor (Grandt et al., Regul. Pept. 51, 151-159, 1994). It was hypothesized that peripheral PYY 3 . 36 inhibits food intake via the Y2R in the arcuate nucleus, an area known to be directly accessible to circulating hormones (Kaha et al., Endocr. Rev. 20, 68-100, 1999).
• IIPSCs inhibitory postsynaptic currents
• the data disclosed herein demonstrates that postprandial levels of PYY 3 . 36 inhibit food intake in more than one mammalian species (e.g. rodents and human subjects) for up to 12 hours, thereby demonstrating a role in regulation of food intake.
• This role can be described as a long term role, such as over a period of several hours (e.g. at least two, three, four, eight, or twelve hours, or from about two to about fifteen hours). This is in contrast to previously characterized gut-derived 'short-term' satiety signals, e.g.
• cholecystokinin (Schwartz et al., Nature 404, 661- 671, 2000; Moran, Nutrition 16, 858- 865, 2000), the effects of which are relatively short-lived (e.g., from about 1-4 hours).
• PYY 3 . 36 The failure of PYY 3 . 36 to inhibit food intake in the 72r-null mice provides evidence that P YY 3 . 36 reduces food intake via a Y2R dependent mechanism.
• the results disclosed herein suggest the existence of a novel gut-hypothalamic pathway in the regulation of feeding, involving postprandial PYY 3 . 36 acting at the arcuate Y2R.
• PYY, and analogs thereof, such as PYY 3 . 36 provide novel therapeutic agents for the treatment of obesity.
• Example 7 Parenterally administered GLP-1 GLP-1 i.e. GLP-1 (7-36) amide (25 nmol/kg) or saline (control) was administered parenterally to non-fasted rats prior to the onset of the dark phase. Exendin 9-39 (20 nmoles/kg) or saline (control) injected into the arcuate nucleus of non-fasted rats. Food intake one hour later was measured.
• GLP-1 and PYY 3 . 36 were injected (intraperitoneally) into non-fasted rats prior to the onset of the dark phase.
• PYY3. 3 6 and GLP-1 were co-administrated IP (P+G group) at doses of GLP-1 30 ⁇ gkg and PYY 3 . 36 3 ⁇ g/kg combined.
• GLP-1 is i.e. GLP-1 (7-36) amide

Priority Applications (1)

Applications Claiming Priority (7)

Related Child Applications (1)

Publications (1)

Family

ID=32992571

Family Applications (2)

Family Applications After (1)

Country Status (5)

Families Citing this family (79)

Family Cites Families (69)

• 2003
  • 2003-01-10 JP JP2003557592A patent/JP4733922B2/ja not_active Expired - Fee Related
  • 2003-01-10 WO PCT/GB2003/000062 patent/WO2003057235A2/en active Application Filing
  • 2003-01-10 AU AU2003201998A patent/AU2003201998C1/en not_active Ceased
  • 2003-01-10 EP EP03700848A patent/EP1474163A2/de not_active Withdrawn
  • 2003-01-10 CA CA002472882A patent/CA2472882A1/en not_active Abandoned
  • 2003-01-10 EP EP10186174.8A patent/EP2329839B1/de not_active Expired - Lifetime
• 2009
  • 2009-07-23 AU AU2009203001A patent/AU2009203001B2/en not_active Ceased
  • 2009-08-24 JP JP2009193064A patent/JP5226628B2/ja not_active Expired - Fee Related
• 2010
  • 2010-12-10 JP JP2010275256A patent/JP2011052018A/ja active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events